1
|
Thommen BT, Dziekan JM, Achcar F, Tjia S, Passecker A, Buczak K, Gumpp C, Schmidt A, Rottmann M, Grüring C, Marti M, Bozdech Z, Brancucci NMB. Genetic validation of PfFKBP35 as an antimalarial drug target. eLife 2023; 12:RP86975. [PMID: 37934560 PMCID: PMC10629825 DOI: 10.7554/elife.86975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2023] Open
Abstract
Plasmodium falciparum accounts for the majority of over 600,000 malaria-associated deaths annually. Parasites resistant to nearly all antimalarials have emerged and the need for drugs with alternative modes of action is thus undoubted. The FK506-binding protein PfFKBP35 has gained attention as a promising drug target due to its high affinity to the macrolide compound FK506 (tacrolimus). Whilst there is considerable interest in targeting PfFKBP35 with small molecules, a genetic validation of this factor as a drug target is missing and its function in parasite biology remains elusive. Here, we show that limiting PfFKBP35 levels are lethal to P. falciparum and result in a delayed death-like phenotype that is characterized by defective ribosome homeostasis and stalled protein synthesis. Our data furthermore suggest that FK506, unlike the action of this drug in model organisms, exerts its antiproliferative activity in a PfFKBP35-independent manner and, using cellular thermal shift assays, we identify putative FK506-targets beyond PfFKBP35. In addition to revealing first insights into the function of PfFKBP35, our results show that FKBP-binding drugs can adopt non-canonical modes of action - with major implications for the development of FK506-derived molecules active against Plasmodium parasites and other eukaryotic pathogens.
Collapse
Affiliation(s)
- Basil T Thommen
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health InstituteAllschwilSwitzerland
- University of BaselBaselSwitzerland
| | - Jerzy M Dziekan
- School of Biological Sciences, Nanyang Technological UniversitySingaporeSingapore
| | - Fiona Achcar
- Wellcome Center for Integrative Parasitology, Institute of Infection, Immunity and Inflammation, University of GlasgowGlasgowUnited Kingdom
- Institute for Parasitology, University of ZurichZurichSwitzerland
| | - Seth Tjia
- School of Biological Sciences, Nanyang Technological UniversitySingaporeSingapore
| | - Armin Passecker
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health InstituteAllschwilSwitzerland
- University of BaselBaselSwitzerland
| | | | - Christin Gumpp
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health InstituteAllschwilSwitzerland
- University of BaselBaselSwitzerland
| | | | - Matthias Rottmann
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health InstituteAllschwilSwitzerland
- University of BaselBaselSwitzerland
| | - Christof Grüring
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health InstituteAllschwilSwitzerland
- University of BaselBaselSwitzerland
| | - Matthias Marti
- Wellcome Center for Integrative Parasitology, Institute of Infection, Immunity and Inflammation, University of GlasgowGlasgowUnited Kingdom
- Institute for Parasitology, University of ZurichZurichSwitzerland
| | - Zbynek Bozdech
- School of Biological Sciences, Nanyang Technological UniversitySingaporeSingapore
| | - Nicolas MB Brancucci
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health InstituteAllschwilSwitzerland
- University of BaselBaselSwitzerland
| |
Collapse
|
2
|
Colina-Vegas L, da Cruz B Silva M, de Souza Pereira C, Isis Barros A, Araújo Nobrega J, Navarro M, Rottmann M, D'Alessandro S, Basilico N, Azevedo Batista A, Moreira DRM. Antimalarial Agents Derived from Metal-Amodiaquine Complexes with Activity in Multiple Stages of the Plasmodium Life Cycle. Chemistry 2023; 29:e202301642. [PMID: 37427863 DOI: 10.1002/chem.202301642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Revised: 07/04/2023] [Accepted: 07/05/2023] [Indexed: 07/11/2023]
Abstract
Malaria is the one of the deadliest infectious diseases worldwide. Chemically, quinolines are excellent ligands for metal coordination and are deployed as drugs for malaria treatment. There is a growing body of evidence indicating that metal complexes can be conjugated with antimalarial quinolines to be used as chemical tools to overcome the disadvantages of quinolines, improving their bioactive speciation, cellular distribution, and subsequently broadening the spectrum of activity to multiple stages of the complex Plasmodium life cycle. In this study, four novel complexes of ruthenium(II)- and gold(I)-containing amodiaquine (AQ) were synthesized, and a careful chemical characterization revealed the precise coordination site of AQ to the metals. Their speciation in solution was investigated, demonstrating the stability of the quinoline-metal bond. RuII - and AuI -AQ complexes were demonstrated to be potent and efficacious in inhibiting parasite growth in multiple stages of the Plasmodium life cycle as assayed in vitro and in vivo. These properties could be attributed to the ability of the metal-AQ complexes to reproduce the suppression of heme detoxification induced by AQ, while also inhibiting other processes in the parasite life cycle; this can be attributed to the action of the metallic species. Altogether, these findings indicate that metal coordination with antimalarial quinolines is a potential chemical tool for drug design and discovery in malaria and other infectious diseases susceptible to quinoline treatment.
Collapse
Affiliation(s)
- Legna Colina-Vegas
- Instituto de Química, Universidade Federal do Rio Grande do Sul, Porto Alegre, CP 91501-970, RS, Brazil
| | | | - Caroline de Souza Pereira
- Departamento de Química, Universidade Federal de Juiz de Fora, Juiz de Fora, CP 36036-900, MG, Brazil
| | - Ariane Isis Barros
- Departamento de Solos e Engenharia Rural, Universidade Federal de Mato Grosso, Cuiabá, CEP 78060-900, MT, Brazil
| | - Joaquim Araújo Nobrega
- Departamento de Química, Universidade Federal de São Carlos, São Carlos, CP 13565-90, SP, Brazil
| | - Maribel Navarro
- Departamento de Química, Universidade Federal de Juiz de Fora, Juiz de Fora, CP 36036-900, MG, Brazil
| | - Matthias Rottmann
- Swiss Tropical & Public Health Institute, 4123, Allschwil, Switzerland
- University of Basel, 4001, Basel, Switzerland
| | - Sarah D'Alessandro
- Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, 20133, Italy
| | - Nicoletta Basilico
- Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche, Universitá degli Studi di Milano, Milan, 20133, Italy
| | - Alzir Azevedo Batista
- Departamento de Química, Universidade Federal de São Carlos, São Carlos, CP 13565-90, SP, Brazil
| | - Diogo R M Moreira
- Instituto Gonçalo Moniz, FIOCRUZ, Salvador, CEP 40296-710, BA, Brazil
| |
Collapse
|
3
|
Mäser P, Bernhard S, Brun R, Burri C, Gagneux S, Hetzel MW, Kaiser M, Lengeler C, Pluschke G, Reus E, Rottmann M, Utzinger J, Warryn L, Wittlin S, Keiser J. Key Contributions by the Swiss Tropical and Public Health Institute Towards New and Better Drugs for Tropical Diseases. Chimia (Aarau) 2023; 77:593-602. [PMID: 38047835 DOI: 10.2533/chimia.2023.593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Accepted: 08/08/2023] [Indexed: 12/05/2023] Open
Abstract
Thanks to its expertise in clinical research, epidemiology, infectious diseases, microbiology, parasitology, public health, translational research and tropical medicine, coupled with deeply rooted partnerships with institutions in low- and middle-income countries (LMICs), the Swiss Tropical and Public Health Institute (Swiss TPH) has been a key contributor in many drug research and development consortia involving academia, pharma and product development partnerships. Our know-how of the maintenance of parasites and their life-cycles in the laboratory, plus our strong ties to research centres and disease control programme managers in LMICs with access to field sites and laboratories, have enabled systems for drug efficacy testing in vitro and in vivo, clinical research, and modelling to support the experimental approaches. Thus, Swiss TPH has made fundamental contributions towards the development of new drugs - and the better use of old drugs - for neglected tropical diseases and infectious diseases of poverty, such as Buruli ulcer, Chagas disease, food-borne trematodiasis (e.g. clonorchiasis, fascioliasis and opisthorchiasis), human African trypanosomiasis, leishmaniasis, malaria, schistosomiasis, soil-transmitted helminthiasis and tuberculosis. In this article, we show case the success stories of molecules to which Swiss TPH has made a substantial contribution regarding their use as anti-infective compounds with the ultimate aim to improve people's health and well-being.
Collapse
Affiliation(s)
- Pascal Mäser
- Dept. Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, CH-4123 Allschwil, Switzerland.
- University of Basel, CH-4001 Basel, Switzerland
| | - Sonja Bernhard
- Swiss Tropical and Public Health Institute, CH-4123 Allschwil, Switzerland.
- University of Basel, CH-4001 Basel, Switzerland
| | - Reto Brun
- Swiss Tropical and Public Health Institute, CH-4123 Allschwil, Switzerland.
- University of Basel, CH-4001 Basel, Switzerland
| | - Christian Burri
- Swiss Tropical and Public Health Institute, CH-4123 Allschwil, Switzerland.
- University of Basel, CH-4001 Basel, Switzerland
| | - Sébastien Gagneux
- Swiss Tropical and Public Health Institute, CH-4123 Allschwil, Switzerland.
- University of Basel, CH-4001 Basel, Switzerland
| | - Manuel W Hetzel
- Swiss Tropical and Public Health Institute, CH-4123 Allschwil, Switzerland.
- University of Basel, CH-4001 Basel, Switzerland
| | - Marcel Kaiser
- Swiss Tropical and Public Health Institute, CH-4123 Allschwil, Switzerland.
- University of Basel, CH-4001 Basel, Switzerland
| | - Christian Lengeler
- Swiss Tropical and Public Health Institute, CH-4123 Allschwil, Switzerland.
- University of Basel, CH-4001 Basel, Switzerland
| | - Gerd Pluschke
- Swiss Tropical and Public Health Institute, CH-4123 Allschwil, Switzerland.
- University of Basel, CH-4001 Basel, Switzerland
| | - Elisabeth Reus
- Swiss Tropical and Public Health Institute, CH-4123 Allschwil, Switzerland.
- University of Basel, CH-4001 Basel, Switzerland
| | - Matthias Rottmann
- Swiss Tropical and Public Health Institute, CH-4123 Allschwil, Switzerland.
- University of Basel, CH-4001 Basel, Switzerland
| | - Jürg Utzinger
- Swiss Tropical and Public Health Institute, CH-4123 Allschwil, Switzerland.
- University of Basel, CH-4001 Basel, Switzerland
| | - Louisa Warryn
- Swiss Tropical and Public Health Institute, CH-4123 Allschwil, Switzerland.
- University of Basel, CH-4001 Basel, Switzerland
| | - Sergio Wittlin
- Swiss Tropical and Public Health Institute, CH-4123 Allschwil, Switzerland.
- University of Basel, CH-4001 Basel, Switzerland
| | - Jennifer Keiser
- Swiss Tropical and Public Health Institute, CH-4123 Allschwil, Switzerland.
- University of Basel, CH-4001 Basel, Switzerland
| |
Collapse
|
4
|
Colling P, Rottmann M, Roese-Koerner L, Gottschalk H. Prediction Quality Meta Regression and Error Meta Classification for Segmented Lidar Point Clouds. INT J ARTIF INTELL T 2023. [DOI: 10.1142/s0218213023600060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
5
|
Asatryan H, Gottschalk H, Lippert M, Rottmann M. A convenient infinite dimensional framework for generative adversarial learning. Electron J Stat 2023. [DOI: 10.1214/23-ejs2104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- Hayk Asatryan
- School of Mathematics and Natural Sciences, University of Wuppertal, Germany
| | - Hanno Gottschalk
- School of Mathematics and Natural Sciences, University of Wuppertal, Germany
| | - Marieke Lippert
- School of Mathematics and Natural Sciences, University of Wuppertal, Germany
| | - Matthias Rottmann
- School of Mathematics and Natural Sciences, University of Wuppertal, Germany
| |
Collapse
|
6
|
Lowe MA, Cardenas A, Valentin JP, Zhu Z, Abendroth J, Castro JL, Class R, Delaunois A, Fleurance R, Gerets H, Gryshkova V, King L, Lorimer DD, MacCoss M, Rowley JH, Rosseels ML, Royer L, Taylor RD, Wong M, Zaccheo O, Chavan VP, Ghule GA, Tapkir BK, Burrows JN, Duffey M, Rottmann M, Wittlin S, Angulo-Barturen I, Jiménez-Díaz MB, Striepen J, Fairhurst KJ, Yeo T, Fidock DA, Cowman AF, Favuzza P, Crespo-Fernandez B, Gamo FJ, Goldberg DE, Soldati-Favre D, Laleu B, de Haro T. Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362. J Med Chem 2022; 65:14121-14143. [PMID: 36216349 DOI: 10.1021/acs.jmedchem.2c01336] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Plasmepsin X (PMX) is an essential aspartyl protease controlling malaria parasite egress and invasion of erythrocytes, development of functional liver merozoites (prophylactic activity), and blocking transmission to mosquitoes, making it a potential multistage drug target. We report the optimization of an aspartyl protease binding scaffold and the discovery of potent, orally active PMX inhibitors with in vivo antimalarial efficacy. Incorporation of safety evaluation early in the characterization of PMX inhibitors precluded compounds with a long human half-life (t1/2) to be developed. Optimization focused on improving the off-target safety profile led to the identification of UCB7362 that had an improved in vitro and in vivo safety profile but a shorter predicted human t1/2. UCB7362 is estimated to achieve 9 log 10 unit reduction in asexual blood-stage parasites with once-daily dosing of 50 mg for 7 days. This work demonstrates the potential to deliver PMX inhibitors with in vivo efficacy to treat malaria.
Collapse
Affiliation(s)
| | | | | | - Zhaoning Zhu
- UCB, 216 Bath Road, Slough SL1 3WE, United Kingdom
| | - Jan Abendroth
- UCB, 7869 NE Day Road West, Bainbridge Island, Washington 98110, United States
| | | | - Reiner Class
- UCB, Chem. du Foriest 1, 1420 Braine-l'Alleud, Belgium
| | | | | | - Helga Gerets
- UCB, Chem. du Foriest 1, 1420 Braine-l'Alleud, Belgium
| | | | - Lloyd King
- UCB, 216 Bath Road, Slough SL1 3WE, United Kingdom
| | - Donald D Lorimer
- UCB, 7869 NE Day Road West, Bainbridge Island, Washington 98110, United States
| | - Malcolm MacCoss
- Bohicket Pharma Consulting LLC, 2556 Seabrook Island Road, Seabrook Island, South Carolina 29455, United States
| | | | | | - Leandro Royer
- UCB, Chem. du Foriest 1, 1420 Braine-l'Alleud, Belgium
| | | | - Melanie Wong
- UCB, 216 Bath Road, Slough SL1 3WE, United Kingdom
| | | | - Vishal P Chavan
- Sai Life Sciences Limited, Plot DS-7, IKP Knowledge Park, Genome Valley, Turkapally, Hyderabad 500078, Telangana, India
| | - Gokul A Ghule
- Sai Life Sciences Limited, Plot DS-7, IKP Knowledge Park, Genome Valley, Turkapally, Hyderabad 500078, Telangana, India
| | - Bapusaheb K Tapkir
- Sai Life Sciences Limited, Plot DS-7, IKP Knowledge Park, Genome Valley, Turkapally, Hyderabad 500078, Telangana, India
| | - Jeremy N Burrows
- Medicines for Malaria Venture, ICC, Route de Pré-Bois 20, 1215 Geneva, Switzerland
| | - Maëlle Duffey
- Medicines for Malaria Venture, ICC, Route de Pré-Bois 20, 1215 Geneva, Switzerland
| | - Matthias Rottmann
- Swiss Tropical and Public Health Institute, Kreuzstrasse 2, CH-4123 Allschwil, Switzerland.,University of Basel, 4002 Basel, Switzerland
| | - Sergio Wittlin
- Swiss Tropical and Public Health Institute, Kreuzstrasse 2, CH-4123 Allschwil, Switzerland.,University of Basel, 4002 Basel, Switzerland
| | - Iñigo Angulo-Barturen
- The Art of Discovery, SL Biscay Science and Technology Park, Astondo Bidea, BIC Bizkaia Building, no. 612, Derio 48160, Bizkaia, Basque Country, Spain
| | - María Belén Jiménez-Díaz
- The Art of Discovery, SL Biscay Science and Technology Park, Astondo Bidea, BIC Bizkaia Building, no. 612, Derio 48160, Bizkaia, Basque Country, Spain
| | - Josefine Striepen
- Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States
| | - Kate J Fairhurst
- Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States
| | - Tomas Yeo
- Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States
| | - David A Fidock
- Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States.,Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, New York 10032, United States
| | - Alan F Cowman
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
| | - Paola Favuzza
- The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia
| | | | | | - Daniel E Goldberg
- Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8051, St. Louis, Missouri 63110, United States
| | - Dominique Soldati-Favre
- Department of Microbiology and Molecular Medicine, Faculty of Medicine, CMU, 1 rue Michel-Servet, CH-1211 Genève 4, Switzerland
| | - Benoît Laleu
- Medicines for Malaria Venture, ICC, Route de Pré-Bois 20, 1215 Geneva, Switzerland
| | | |
Collapse
|
7
|
Schneider L, Albrecht C, Grehn C, Gryc T, Knop S, Siegler G, Bott A, Rottmann M, Blos M, Linnemann U, Köhler J, Jakob J, Hohenberger P, Papadopoulos T, Meyer C, Mordstein V, B. Stein, Gazdag L, Reichert B, Augustin M. 1500P Radiochemotherapy with gemcitabine as a radiosensitizer in patients with soft tissue sarcomas. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
8
|
Khandelwal A, Arez F, Alves PM, Badolo L, Brito C, Fischli C, Fontinha D, Oeuvray C, Prudêncio M, Rottmann M, Wilkins J, Yalkinoglu Ö, Bagchus WM, Spangenberg T. Translation of liver stage activity of M5717, a Plasmodium elongation factor 2 inhibitor: from bench to bedside. Malar J 2022; 21:151. [PMID: 35570264 PMCID: PMC9107587 DOI: 10.1186/s12936-022-04171-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Accepted: 04/25/2022] [Indexed: 11/10/2022] Open
Abstract
Background Targeting the asymptomatic liver stage of Plasmodium infection through chemoprevention could become a key intervention to reduce malaria-associated incidence and mortality. Methods M5717, a Plasmodium elongation factor 2 inhibitor, was assessed in vitro and in vivo with readily accessible Plasmodium berghei parasites. In an animal refinement, reduction, replacement approach, the in vitro IC99 value was used to feed a Population Pharmacokinetics modelling and simulation approach to determine meaningful effective doses for a subsequent Plasmodium sporozoite-induced volunteer infection study. Results Doses of 100 and 200 mg would provide exposures exceeding IC99 in 96 and 100% of the simulated population, respectively. Conclusions This approach has the potential to accelerate the search for new anti-malarials, to reduce the number of healthy volunteers needed in a clinical study and decrease and refine the animal use in the preclinical phase. Graphical Abstract ![]()
Collapse
|
9
|
Hirsch AKH, Diamanti E, Hamed MM, Lacour A, Bravo P, Illarionov B, Fischer M, Rottmann M, Witschel M. Targeting the IspD enzyme in the MEP pathway: identification of a novel fragment class. ChemMedChem 2021; 17:e202100679. [PMID: 34918860 PMCID: PMC9305118 DOI: 10.1002/cmdc.202100679] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 12/14/2021] [Indexed: 12/01/2022]
Abstract
The enzymes of the 2‐C‐methylerythritol‐d‐erythritol 4‐phosphate (MEP) pathway (MEP pathway or non‐mevalonate pathway) are responsible for the synthesis of universal precursors of the large and structurally diverse family of isoprenoids. This pathway is absent in humans, but present in many pathogenic organisms and plants, making it an attractive source of drug targets. Here, we present a high‐throughput screening approach that led to the discovery of a novel fragment hit active against the third enzyme of the MEP pathway, PfIspD. A systematic SAR investigation afforded a novel chemical structure with a balanced activity–stability profile (16). Using a homology model of PfIspD, we proposed a putative binding mode for our newly identified inhibitors that sets the stage for structure‐guided optimization.
Collapse
Affiliation(s)
- Anna Katharina Herta Hirsch
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Drug Design and Optimization, Campus E8.1, 66123, Saarbrücken, GERMANY
| | - Eleonora Diamanti
- Helmholtz-Institut fur Pharmazeutische Forschung Saarland, DDOP, Campus E8 1, Saarbrücken, 66123, Saarbrücken, GERMANY
| | - Mostafa M Hamed
- Helmholtz-Institut fur Pharmazeutische Forschung Saarland, DDOP, Campus E8 1, Saarbrücken, 66123, Saarbrücken, GERMANY
| | - Antoine Lacour
- Helmholtz-Institut fur Pharmazeutische Forschung Saarland, DDOP, Campus E8 1, Saarbrücken, 66123, Saarbrücken, GERMANY
| | - Patricia Bravo
- Swiss Tropical and Public Health Institute: Schweizerisches Tropen- und Public Health-Institut, Parasite Chemotherapy Unit, SWITZERLAND
| | | | - Markus Fischer
- University of Hamburg: Universitat Hamburg, School of Food Science, GERMANY
| | - Matthias Rottmann
- Swiss Tropical and Public Health Institute: Schweizerisches Tropen- und Public Health-Institut, Parasite Chemotherapy Unit, 4002, Basel, SWITZERLAND
| | | |
Collapse
|
10
|
Ropponen HK, Bader CD, Diamanti E, Illarionov B, Rottmann M, Fischer M, Witschel M, Müller R, Hirsch AKH. Search for the Active Ingredients from a 2-Aminothiazole DMSO Stock Solution with Antimalarial Activity. ChemMedChem 2021; 16:2089-2093. [PMID: 33844432 PMCID: PMC8360061 DOI: 10.1002/cmdc.202100067] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Revised: 03/17/2021] [Indexed: 12/31/2022]
Abstract
Chemical decomposition of DMSO stock solutions is a common incident that can mislead biological screening campaigns. Here, we share our case study of 2‐aminothiazole 1, originating from an antimalarial class that undergoes chemical decomposition in DMSO at room temperature. As previously measured biological activities observed against Plasmodium falciparum NF54 and for the target enzyme PfIspE were not reproducible for a fresh batch, we tackled the challenge to understand where the activity originated from. Solvent‐ and temperature‐dependent studies using HRMS and NMR spectroscopy to monitor the decomposition led to the isolation and in vitro evaluation of several fractions against PfIspE. After four days of decomposition, we successfully isolated the oxygenated and dimerised compounds using SFC purification and correlated the observed activities to them. Due to the unstable nature of the two isolates, it is likely that they undergo further decomposition contributing to the overall instability of the compound.
Collapse
Affiliation(s)
- Henni-Karoliina Ropponen
- Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz-Centre for Infection Research (HZI), Campus E8.1, 66123, Saarbrücken, Germany.,Department of Pharmacy, Saarland University, Campus E8.1, 66123, Saarbrücken, Germany
| | - Chantal D Bader
- Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz-Centre for Infection Research (HZI), Campus E8.1, 66123, Saarbrücken, Germany.,Department of Pharmacy, Saarland University, Campus E8.1, 66123, Saarbrücken, Germany
| | - Eleonora Diamanti
- Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz-Centre for Infection Research (HZI), Campus E8.1, 66123, Saarbrücken, Germany.,Department of Pharmacy, Saarland University, Campus E8.1, 66123, Saarbrücken, Germany.,Helmholtz International Lab for Anti-Infectives, Campus E8.1, 66123, Saarbrücken, Germany
| | - Boris Illarionov
- Hamburg School of Food Science, University of Hamburg, Grindelallee 117, 20146, Hamburg, Germany
| | - Matthias Rottmann
- Swiss Tropical and Public Health Institute, Socinstrasse 57, 4002, Basel, Switzerland.,Universität Basel, Petersplatz 1, 4003, Basel, Switzerland
| | - Markus Fischer
- Hamburg School of Food Science, University of Hamburg, Grindelallee 117, 20146, Hamburg, Germany
| | | | - Rolf Müller
- Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz-Centre for Infection Research (HZI), Campus E8.1, 66123, Saarbrücken, Germany.,Department of Pharmacy, Saarland University, Campus E8.1, 66123, Saarbrücken, Germany.,Helmholtz International Lab for Anti-Infectives, Campus E8.1, 66123, Saarbrücken, Germany
| | - Anna K H Hirsch
- Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz-Centre for Infection Research (HZI), Campus E8.1, 66123, Saarbrücken, Germany.,Department of Pharmacy, Saarland University, Campus E8.1, 66123, Saarbrücken, Germany.,Helmholtz International Lab for Anti-Infectives, Campus E8.1, 66123, Saarbrücken, Germany
| |
Collapse
|
11
|
Ropponen HK, Diamanti E, Siemens A, Illarionov B, Haupenthal J, Fischer M, Rottmann M, Witschel M, Hirsch AKH. Assessment of the rules related to gaining activity against Gram-negative bacteria. RSC Med Chem 2021; 12:593-601. [PMID: 34046630 PMCID: PMC8128065 DOI: 10.1039/d0md00409j] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2020] [Accepted: 01/30/2021] [Indexed: 11/21/2022] Open
Abstract
In the search for new antibacterial compounds, we repositioned an antimalarial compound class by derivatising it based on the so-called "eNTRy" rules for enhanced accumulation into Gram-negative bacteria. We designed, synthesised and evaluated a small library of amino acid modified compounds together with the respective Boc-protected analogues, leading to no substantial improvement in antibacterial activity against Escherichia coli wild-type K12, whereas more distinct activity differences were observed in E. coli mutant strains ΔtolC, D22, ΔacrB and BL21(DE3)omp8. A comparison of the activity results of the E. coli mutants with respect to the known rules related to enhanced activity against Gram-negative bacteria revealed that applicability of the rules is not always ensured. Out of the four amino acids used in this study, glycine derivatives showed highest antibacterial activity, although still suffering from efflux issues.
Collapse
Affiliation(s)
- Henni-Karoliina Ropponen
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI) Campus Building E8.1 66123 Saarbrücken Germany
- Department of Pharmacy, Saarland University Campus Building E8.1 66123 Saarbrücken Germany
| | - Eleonora Diamanti
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI) Campus Building E8.1 66123 Saarbrücken Germany
| | - Alexandra Siemens
- Hamburg School of Food Science, University of Hamburg Grindelallee 117 20146 Hamburg Germany
| | - Boris Illarionov
- Hamburg School of Food Science, University of Hamburg Grindelallee 117 20146 Hamburg Germany
| | - Jörg Haupenthal
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI) Campus Building E8.1 66123 Saarbrücken Germany
| | - Markus Fischer
- Hamburg School of Food Science, University of Hamburg Grindelallee 117 20146 Hamburg Germany
| | - Matthias Rottmann
- Swiss Tropical and Public Health Institute Socinstrasse 57 4002 Basel Switzerland
- Universität Basel Petersplatz 1 4003 Basel Switzerland
| | | | - Anna K H Hirsch
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI) Campus Building E8.1 66123 Saarbrücken Germany
- Department of Pharmacy, Saarland University Campus Building E8.1 66123 Saarbrücken Germany
| |
Collapse
|
12
|
Favuzza P, de Lera Ruiz M, Thompson JK, Triglia T, Ngo A, Steel RWJ, Vavrek M, Christensen J, Healer J, Boyce C, Guo Z, Hu M, Khan T, Murgolo N, Zhao L, Penington JS, Reaksudsan K, Jarman K, Dietrich MH, Richardson L, Guo KY, Lopaticki S, Tham WH, Rottmann M, Papenfuss T, Robbins JA, Boddey JA, Sleebs BE, Sabroux HJ, McCauley JA, Olsen DB, Cowman AF. Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle. Cell Host Microbe 2020; 27:642-658.e12. [PMID: 32109369 PMCID: PMC7146544 DOI: 10.1016/j.chom.2020.02.005] [Citation(s) in RCA: 73] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2019] [Revised: 12/22/2019] [Accepted: 02/11/2020] [Indexed: 01/07/2023]
Abstract
Artemisin combination therapy (ACT) is the main treatment option for malaria, which is caused by the intracellular parasite Plasmodium. However, increased resistance to ACT highlights the importance of finding new drugs. Recently, the aspartic proteases Plasmepsin IX and X (PMIX and PMX) were identified as promising drug targets. In this study, we describe dual inhibitors of PMIX and PMX, including WM382, that block multiple stages of the Plasmodium life cycle. We demonstrate that PMX is a master modulator of merozoite invasion and direct maturation of proteins required for invasion, parasite development, and egress. Oral administration of WM382 cured mice of P. berghei and prevented blood infection from the liver. In addition, WM382 was efficacious against P. falciparum asexual infection in humanized mice and prevented transmission to mosquitoes. Selection of resistant P. falciparum in vitro was not achievable. Together, these show that dual PMIX and PMX inhibitors are promising candidates for malaria treatment and prevention.
Collapse
Affiliation(s)
- Paola Favuzza
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; University of Melbourne, Melbourne, VIC 3010, Australia
| | | | - Jennifer K Thompson
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia
| | - Tony Triglia
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia
| | - Anna Ngo
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia
| | - Ryan W J Steel
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; University of Melbourne, Melbourne, VIC 3010, Australia
| | - Marissa Vavrek
- Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA 19486, USA
| | - Janni Christensen
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; University of Melbourne, Melbourne, VIC 3010, Australia
| | - Julie Healer
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; University of Melbourne, Melbourne, VIC 3010, Australia
| | | | - Zhuyan Guo
- Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA 19486, USA
| | - Mengwei Hu
- Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA 19486, USA
| | - Tanweer Khan
- Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA 19486, USA
| | - Nicholas Murgolo
- Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA 19486, USA
| | - Lianyun Zhao
- Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA 19486, USA
| | | | - Kitsanapong Reaksudsan
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; University of Melbourne, Melbourne, VIC 3010, Australia
| | - Kate Jarman
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia
| | - Melanie H Dietrich
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; University of Melbourne, Melbourne, VIC 3010, Australia
| | - Lachlan Richardson
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; University of Melbourne, Melbourne, VIC 3010, Australia
| | - Kai-Yuan Guo
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; University of Melbourne, Melbourne, VIC 3010, Australia
| | - Sash Lopaticki
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia
| | - Wai-Hong Tham
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; University of Melbourne, Melbourne, VIC 3010, Australia
| | | | - Tony Papenfuss
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; University of Melbourne, Melbourne, VIC 3010, Australia
| | | | - Justin A Boddey
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; University of Melbourne, Melbourne, VIC 3010, Australia
| | - Brad E Sleebs
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; University of Melbourne, Melbourne, VIC 3010, Australia
| | - Hélène Jousset Sabroux
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; University of Melbourne, Melbourne, VIC 3010, Australia
| | - John A McCauley
- Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA 19486, USA
| | - David B Olsen
- Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA 19486, USA.
| | - Alan F Cowman
- The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; University of Melbourne, Melbourne, VIC 3010, Australia.
| |
Collapse
|
13
|
Mueller R, Reddy V, Nchinda AT, Mebrahtu F, Taylor D, Lawrence N, Tanner L, Barnabe M, Eyermann CJ, Zou B, Kondreddi RR, Lakshminarayana SB, Rottmann M, Street LJ, Chibale K. Lerisetron Analogues with Antimalarial Properties: Synthesis, Structure-Activity Relationship Studies, and Biological Assessment. ACS Omega 2020; 5:6967-6982. [PMID: 32258933 PMCID: PMC7114883 DOI: 10.1021/acsomega.0c00327] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Accepted: 03/05/2020] [Indexed: 06/11/2023]
Abstract
A phenotypic whole cell high-throughput screen against the asexual blood and liver stages of the malaria parasite identified a benzimidazole chemical series. Among the hits were the antiemetic benzimidazole drug Lerisetron 1 (IC50 NF54 = 0.81 μM) and its methyl-substituted analogue 2 (IC50 NF54 = 0.098 μM). A medicinal chemistry hit to lead effort led to the identification of chloro-substituted analogue 3 with high potency against the drug-sensitive NF54 (IC50 NF54 = 0.062 μM) and multidrug-resistant K1 (IC50 K1 = 0.054 μM) strains of the human malaria parasite Plasmodium falciparum. Compounds 2 and 3 gratifyingly showed in vivo efficacy in both Plasmodium berghei and P. falciparum mouse models of malaria. Cardiotoxicity risk as expressed in strong inhibition of the human ether-a-go-go-related gene (hERG) potassium channel was identified as a major liability to address. This led to the synthesis and biological assessment of around 60 analogues from which several compounds with improved antiplasmodial potency, relative to the lead compound 3, were identified.
Collapse
Affiliation(s)
- Rudolf Mueller
- Drug
Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
| | - Virsinha Reddy
- Drug
Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
| | - Aloysius T. Nchinda
- Drug
Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
| | - Fanuel Mebrahtu
- Drug
Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
| | - Dale Taylor
- Drug
Discovery and Development Centre (H3D), Division of Clinical Pharmacology,
Department of Medicine, University of Cape
Town, Observatory 7925, South Africa
| | - Nina Lawrence
- Drug
Discovery and Development Centre (H3D), Division of Clinical Pharmacology,
Department of Medicine, University of Cape
Town, Observatory 7925, South Africa
| | - Lloyd Tanner
- Drug
Discovery and Development Centre (H3D), Division of Clinical Pharmacology,
Department of Medicine, University of Cape
Town, Observatory 7925, South Africa
| | - Marine Barnabe
- Drug
Discovery and Development Centre (H3D), Division of Clinical Pharmacology,
Department of Medicine, University of Cape
Town, Observatory 7925, South Africa
| | - Charles J. Eyermann
- Drug
Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
| | - Bin Zou
- Shanghai
Blueray Biopharma Co. LTD, Block 3, 576 Libing Road, Pudong New District, Shanghai 201301, China
| | - Ravinder R. Kondreddi
- PJS
Pharma Pvt. Ltd., Plot
No. 103/1, Phase II, IDA Cherlapally, Hyderabad 500051, India
| | - Suresh B. Lakshminarayana
- Novartis
Institute for Tropical Diseases, 5300 Chiron Way, Emeryville, California 94608, United States
| | - Matthias Rottmann
- Department
of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, CH-4051 Basel, Switzerland
- University
of Basel, 4002 Basel, Switzerland
| | - Leslie J. Street
- Drug
Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
| | - Kelly Chibale
- Drug
Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
- South
African Medical Research Council Drug Discovery and Development Research
Unit, Department of Chemistry & Institute of Infectious Disease
and Molecular Medicine, University of Cape
Town, Rondebosch 7701, South Africa
| |
Collapse
|
14
|
Burgert L, Rottmann M, Wittlin S, Gobeau N, Krause A, Dingemanse J, Möhrle JJ, Penny MA. Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development. Sci Rep 2020; 10:4410. [PMID: 32157151 PMCID: PMC7064600 DOI: 10.1038/s41598-020-61304-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Accepted: 02/20/2020] [Indexed: 11/23/2022] Open
Abstract
Emerging drug resistance and high-attrition rates in early and late stage drug development necessitate accelerated development of antimalarial compounds. However, systematic and meaningful translation of drug efficacy and host-parasite dynamics between preclinical testing stages is missing. We developed an ensemble of mathematical within-host parasite growth and antimalarial action models, fitted to extensive data from four antimalarials with different modes of action, to assess host-parasite interactions in two preclinical drug testing systems of murine parasite P. berghei in mice, and human parasite P. falciparum in immune-deficient mice. We find properties of the host-parasite system, namely resource availability, parasite maturation and virulence, drive P. berghei dynamics and drug efficacy, whereas experimental constraints primarily influence P. falciparum infection and drug efficacy. Furthermore, uninvestigated parasite behavior such as dormancy influences parasite recrudescence following non-curative treatment and requires further investigation. Taken together, host-parasite interactions should be considered for meaningful translation of pharmacodynamic properties between murine systems and for predicting human efficacious treatment.
Collapse
Affiliation(s)
- Lydia Burgert
- Swiss Tropical and Public Health Institute, Basel, Switzerland.,University of Basel, Basel, Switzerland
| | - Matthias Rottmann
- Swiss Tropical and Public Health Institute, Basel, Switzerland.,University of Basel, Basel, Switzerland
| | - Sergio Wittlin
- Swiss Tropical and Public Health Institute, Basel, Switzerland.,University of Basel, Basel, Switzerland
| | | | - Andreas Krause
- Idorsia Pharmaceuticals Ltd, Clinical Pharmacology, Allschwil, Switzerland
| | - Jasper Dingemanse
- Idorsia Pharmaceuticals Ltd, Clinical Pharmacology, Allschwil, Switzerland
| | - Jörg J Möhrle
- Swiss Tropical and Public Health Institute, Basel, Switzerland.,University of Basel, Basel, Switzerland.,Medicines for Malaria Venture, Geneva, Switzerland
| | - Melissa A Penny
- Swiss Tropical and Public Health Institute, Basel, Switzerland. .,University of Basel, Basel, Switzerland.
| |
Collapse
|
15
|
Arez F, Rebelo SP, Fontinha D, Simão D, Martins TR, Machado M, Fischli C, Oeuvray C, Badolo L, Carrondo MJT, Rottmann M, Spangenberg T, Brito C, Greco B, Prudêncio M, Alves PM. Flexible 3D Cell-Based Platforms for the Discovery and Profiling of Novel Drugs Targeting Plasmodium Hepatic Infection. ACS Infect Dis 2019; 5:1831-1842. [PMID: 31479238 DOI: 10.1021/acsinfecdis.9b00144] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The restricted pipeline of drugs targeting the liver stage of Plasmodium infection reflects the scarcity of cell models that mimic the human hepatic phenotype and drug metabolism, as well as Plasmodium hepatic infection. Using stirred-tank culture systems, spheroids of human hepatic cell lines were generated, sustaining a stable hepatic phenotype over 4 weeks of culture. Spheroids were employed in the establishment of 3D Plasmodium berghei infection platforms that relied on static or dynamic culture conditions. P. berghei invasion and development were recapitulated in the hepatic spheroids, yielding blood-infective merozoites. The translational potential of the 3D platforms was demonstrated by comparing the in vitro minimum inhibitory concentration of M5717, a compound under clinical development, with in vivo plasma concentrations that clear liver stage P. berghei in mice. Our results show that the 3D platforms are flexible and scalable and can predict the efficacy of antiplasmodial therapies, constituting a powerful tool for integration in drug discovery programs.
Collapse
Affiliation(s)
- Francisca Arez
- iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2780-901 Oeiras, Portugal
- Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avenida da República, 2780-157 Oeiras, Portugal
| | - Sofia P. Rebelo
- iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2780-901 Oeiras, Portugal
- Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avenida da República, 2780-157 Oeiras, Portugal
| | - Diana Fontinha
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal
| | - Daniel Simão
- iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2780-901 Oeiras, Portugal
- Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avenida da República, 2780-157 Oeiras, Portugal
| | - Tatiana R. Martins
- iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2780-901 Oeiras, Portugal
- Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avenida da República, 2780-157 Oeiras, Portugal
| | - Marta Machado
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal
| | - Christoph Fischli
- Swiss Tropical and Public Health Institute, Basel 4051, Switzerland
- University of Basel, Basel 4003, Switzerland
| | - Claude Oeuvray
- Global Health Institute of Merck, Ares Trading S.A., a subsidiary of Merck KGaA, Darmstadt, Germany, 1262 Eysins, Switzerland
| | - Lassina Badolo
- Discovery and Development Technologies, Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany
| | - Manuel J. T. Carrondo
- iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2780-901 Oeiras, Portugal
- Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avenida da República, 2780-157 Oeiras, Portugal
| | - Matthias Rottmann
- Swiss Tropical and Public Health Institute, Basel 4051, Switzerland
- University of Basel, Basel 4003, Switzerland
| | - Thomas Spangenberg
- Global Health Institute of Merck, Ares Trading S.A., a subsidiary of Merck KGaA, Darmstadt, Germany, 1262 Eysins, Switzerland
| | - Catarina Brito
- iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2780-901 Oeiras, Portugal
- Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avenida da República, 2780-157 Oeiras, Portugal
| | - Beatrice Greco
- Global Health Institute of Merck, Ares Trading S.A., a subsidiary of Merck KGaA, Darmstadt, Germany, 1262 Eysins, Switzerland
| | - Miguel Prudêncio
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal
| | - Paula M. Alves
- iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2780-901 Oeiras, Portugal
- Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avenida da República, 2780-157 Oeiras, Portugal
| |
Collapse
|
16
|
Zobeiri M, Chaudhary R, Blaich A, Rottmann M, Herrmann S, Meuth P, Bista P, Kanyshkova T, Lüttjohann A, Narayanan V, Hundehege P, Meuth SG, Romanelli MN, Urbano FJ, Pape HC, Budde T, Ludwig A. The Hyperpolarization-Activated HCN4 Channel is Important for Proper Maintenance of Oscillatory Activity in the Thalamocortical System. Cereb Cortex 2019; 29:2291-2304. [PMID: 30877792 PMCID: PMC6458902 DOI: 10.1093/cercor/bhz047] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2018] [Revised: 02/15/2019] [Accepted: 02/21/2019] [Indexed: 11/14/2022] Open
Abstract
Hyperpolarization-activated cation channels are involved, among other functions, in learning and memory, control of synaptic transmission and epileptogenesis. The importance of the HCN1 and HCN2 isoforms for brain function has been demonstrated, while the role of HCN4, the third major neuronal HCN subunit, is not known. Here we show that HCN4 is essential for oscillatory activity in the thalamocortical (TC) network. HCN4 is selectively expressed in various thalamic nuclei, excluding the thalamic reticular nucleus. HCN4-deficient TC neurons revealed a massive reduction of Ih and strongly reduced intrinsic burst firing, whereas the current was normal in cortical pyramidal neurons. In addition, evoked bursting in a thalamic slice preparation was strongly reduced in the mutant mice probes. HCN4-deficiency also significantly slowed down thalamic and cortical oscillations during active wakefulness. Taken together, these results establish that thalamic HCN4 channels are essential for the production of rhythmic intrathalamic oscillations and determine regular TC oscillatory activity during alert states.
Collapse
Affiliation(s)
- Mehrnoush Zobeiri
- Institut für Physiologie I, Westfälische Wilhelms-Universität, Münster, Germany
| | - Rahul Chaudhary
- Institut für Physiologie I, Westfälische Wilhelms-Universität, Münster, Germany
| | - Anne Blaich
- Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
| | - Matthias Rottmann
- Institut für Physiologie I, Westfälische Wilhelms-Universität, Münster, Germany
| | - Stefan Herrmann
- Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
| | - Patrick Meuth
- Klinik für Neurologie mit Institut für Translationale Neurologie, Westfälische Wilhelms-Universität, Münster, Germany
| | - Pawan Bista
- Institut für Physiologie I, Westfälische Wilhelms-Universität, Münster, Germany
| | - Tatyana Kanyshkova
- Institut für Physiologie I, Westfälische Wilhelms-Universität, Münster, Germany
| | - Annika Lüttjohann
- Institut für Physiologie I, Westfälische Wilhelms-Universität, Münster, Germany
| | - Venu Narayanan
- Klinik für Neurologie mit Institut für Translationale Neurologie, Westfälische Wilhelms-Universität, Münster, Germany
| | - Petra Hundehege
- Klinik für Neurologie mit Institut für Translationale Neurologie, Westfälische Wilhelms-Universität, Münster, Germany
| | - Sven G Meuth
- Klinik für Neurologie mit Institut für Translationale Neurologie, Westfälische Wilhelms-Universität, Münster, Germany
| | - Maria Novella Romanelli
- Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, Italy
| | | | - Hans-Christian Pape
- Institut für Physiologie I, Westfälische Wilhelms-Universität, Münster, Germany
| | - Thomas Budde
- Institut für Physiologie I, Westfälische Wilhelms-Universität, Münster, Germany
| | - Andreas Ludwig
- Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
| |
Collapse
|
17
|
Grogg M, Hilvert D, Ebert MO, Beck AK, Seebach D, Kurth F, Dittrich PS, Sparr C, Wittlin S, Rottmann M, Mäser P. Cell Penetration, Herbicidal Activity, and in-vivo-Toxicity of Oligo-Arginine Derivatives and of Novel Guanidinium-Rich Compounds Derived from the Biopolymer Cyanophycin. Helv Chim Acta 2018; 101. [PMID: 30905972 DOI: 10.1002/hlca.201800112] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Oligo-arginines are thoroughly studied cell-penetrating peptides (CPPs, Figures 1 and 2). Previous in-vitro investigations with the octaarginine salt of the phosphonate fosmidomycin (herbicide and anti-malaria drug) have shown a 40-fold parasitaemia inhibition with P. falciparum, compared to fosmidomycin alone (Figure 3). We have now tested this salt, as well as the corresponding phosphinate salt of the herbicide glufosinate, for herbicidal activity with whole plants by spray application, hoping for increased activities, i.e. decreased doses. However, both salts showed low herbicidal activity, indicating poor foliar uptake (Table 1). Another pronounced difference between in-vitro and in-vivo activity was demonstrated with various cell-penetrating octaarginine salts of fosmidomycin: intravenous injection to mice caused exitus of the animals within minutes, even at doses as low as 1.4 μmol/kg (Table 2). The results show that use of CPPs for drug delivery, for instance to cancer cells and tissues, must be considered with due care. The biopolymer cyanophycin is a poly-aspartic acid containing argininylated side chains (Figure 4); its building block is the dipeptide H-βAsp-αArg-OH (H-Adp-OH). To test and compare the biological properties with those of octaarginines we synthesized Adp8-derivatives (Figure 5). Intravenouse injection of H-Adp8-NH2 into the tail vein of mice with doses as high as 45 μmol/kg causes no symptoms whatsoever (Table 3), but H-Adp8-NH2 is not cell penetrating (HEK293 and MCF-7 cells, Figure 6). On the other hand, the fluorescently labeled octamers FAM-(Adp(OMe))8-NH2 and FAM-(Adp(NMe2))8-NH2 with ester and amide groups in the side chains exhibit mediocre to high cell-wall permeability (Figure 6), and are toxic (Table 3). Possible reasons for this behavior are discussed (Figure 7) and corresponding NMR spectra are presented (Figure 8).
Collapse
Affiliation(s)
- Marcel Grogg
- Laboratorium für Organische Chemie, Departement Chemie und Angewandte Biowissenschaften, ETH-Zürich, Hönggerberg HCI, Vladimir-Prelog-Weg 3, CH-8093 Zürich, Switzerland
| | - Donald Hilvert
- Laboratorium für Organische Chemie, Departement Chemie und Angewandte Biowissenschaften, ETH-Zürich, Hönggerberg HCI, Vladimir-Prelog-Weg 3, CH-8093 Zürich, Switzerland
| | - Marc-Olivier Ebert
- Laboratorium für Organische Chemie, Departement Chemie und Angewandte Biowissenschaften, ETH-Zürich, Hönggerberg HCI, Vladimir-Prelog-Weg 3, CH-8093 Zürich, Switzerland
| | - Albert K Beck
- Laboratorium für Organische Chemie, Departement Chemie und Angewandte Biowissenschaften, ETH-Zürich, Hönggerberg HCI, Vladimir-Prelog-Weg 3, CH-8093 Zürich, Switzerland
| | - Dieter Seebach
- Laboratorium für Organische Chemie, Departement Chemie und Angewandte Biowissenschaften, ETH-Zürich, Hönggerberg HCI, Vladimir-Prelog-Weg 3, CH-8093 Zürich, Switzerland
| | - Felix Kurth
- Department of Biosystems Science and Engineering, ETH Zürich, BSD H 368, Mattenstrasse 26, CH-4058 Basel, Switzerland
| | - Petra S Dittrich
- Department of Biosystems Science and Engineering, ETH Zürich, BSD H 368, Mattenstrasse 26, CH-4058 Basel, Switzerland
| | - Christof Sparr
- Department of Chemistry, University of Basel, St. Johanns-Ring 19, CH-4056 Basel, Switzerland
| | - Sergio Wittlin
- Swiss Tropical and Public Health Institute, Socinstrasse 57, CH-4051 Basel, Switzerland
| | - Matthias Rottmann
- Swiss Tropical and Public Health Institute, Socinstrasse 57, CH-4051 Basel, Switzerland
| | - Pascal Mäser
- Swiss Tropical and Public Health Institute, Socinstrasse 57, CH-4051 Basel, Switzerland
| |
Collapse
|
18
|
Wetzka S, Gallwas J, Hasbargen U, Breitkreuz T, Rottmann M, Mahner S, Dannecker C. Einfluss von Konisation auf die Frühgeburtenrate und das perinatale Outcome: Eine retrospektive Analyse der Daten zur externen stationären Qualitätssicherung für die Erfassungsjahre 2009 – 2014. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- S Wetzka
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Ludwig-Maximilians-Universität München, München, Deutschland
| | - J Gallwas
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Ludwig-Maximilians-Universität München, München, Deutschland
| | - U Hasbargen
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Ludwig-Maximilians-Universität München, München, Deutschland
| | - T Breitkreuz
- Institut für angewandte Qualitätsförderung und Forschung im Gesundheitswesen (AQUA), Göttingen, Deutschland
| | - M Rottmann
- Tumorregister München (TRM), Bayerisches Krebsregister – Regionalzentrum München, München, Deutschland
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Ludwig-Maximilians-Universität München, München, Deutschland
| | - C Dannecker
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Ludwig-Maximilians-Universität München, München, Deutschland
| |
Collapse
|
19
|
Schwertz G, Witschel MC, Rottmann M, Leartsakulpanich U, Chitnumsub P, Jaruwat A, Amornwatcharapong W, Ittarat W, Schäfer A, Aponte RA, Trapp N, Chaiyen P, Diederich F. Potent Inhibitors ofPlasmodialSerine Hydroxymethyltransferase (SHMT) Featuring a Spirocyclic Scaffold. ChemMedChem 2018; 13:931-943. [DOI: 10.1002/cmdc.201800053] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Revised: 02/25/2018] [Indexed: 12/19/2022]
Affiliation(s)
- Geoffrey Schwertz
- Laboratorium für Organische Chemie; ETH Zürich; Vladimir-Prelog-Weg 3 8093 Zürich Switzerland
| | | | - Matthias Rottmann
- Swiss Tropical and Public Health Institute (SwissTPH); Socinstrasse 57 4051 Basel Switzerland
- Universität Basel; Petersplatz 1 4003 Basel Switzerland
| | - Ubolsree Leartsakulpanich
- National Center for Genetic Engineering and Biotechnology; 113 Thailand Science Park, Phahonyothin Road Pathumthani 12120 Thailand
| | - Penchit Chitnumsub
- National Center for Genetic Engineering and Biotechnology; 113 Thailand Science Park, Phahonyothin Road Pathumthani 12120 Thailand
| | - Aritsara Jaruwat
- National Center for Genetic Engineering and Biotechnology; 113 Thailand Science Park, Phahonyothin Road Pathumthani 12120 Thailand
| | - Watcharee Amornwatcharapong
- Department of Biochemistry and Center for Excellence in Protein and Enzyme Technology, Faculty of Science; Mahidol University; 272 Rama VI Road Bangkok 10400 Thailand
| | - Wanwipa Ittarat
- National Center for Genetic Engineering and Biotechnology; 113 Thailand Science Park, Phahonyothin Road Pathumthani 12120 Thailand
| | - Anja Schäfer
- Swiss Tropical and Public Health Institute (SwissTPH); Socinstrasse 57 4051 Basel Switzerland
- Universität Basel; Petersplatz 1 4003 Basel Switzerland
| | | | - Nils Trapp
- Laboratorium für Organische Chemie; ETH Zürich; Vladimir-Prelog-Weg 3 8093 Zürich Switzerland
| | - Pimchai Chaiyen
- Department of Biochemistry and Center for Excellence in Protein and Enzyme Technology, Faculty of Science; Mahidol University; 272 Rama VI Road Bangkok 10400 Thailand
- Department of Biomolecular Science and Engineering, School of Biomolecular Science & Engineering; Vidyasirimedhi Institute of Science and Technology (VISTEC); Wangchan Valley Rayong 21210 Thailand
| | - François Diederich
- Laboratorium für Organische Chemie; ETH Zürich; Vladimir-Prelog-Weg 3 8093 Zürich Switzerland
| |
Collapse
|
20
|
Levatić J, Pavić K, Perković I, Uzelac L, Ester K, Kralj M, Kaiser M, Rottmann M, Supek F, Zorc B. Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity. Eur J Med Chem 2018; 146:651-667. [DOI: 10.1016/j.ejmech.2018.01.062] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Revised: 01/16/2018] [Accepted: 01/18/2018] [Indexed: 01/24/2023]
|
21
|
Schwertz G, Frei MS, Witschel MC, Rottmann M, Leartsakulpanich U, Chitnumsub P, Jaruwat A, Ittarat W, Schäfer A, Aponte RA, Trapp N, Mark K, Chaiyen P, Diederich F. Conformational Aspects in the Design of Inhibitors for Serine Hydroxymethyltransferase (SHMT): Biphenyl, Aryl Sulfonamide, and Aryl Sulfone Motifs. Chemistry 2017; 23:14345-14357. [DOI: 10.1002/chem.201703244] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Revised: 08/15/2017] [Indexed: 12/31/2022]
Affiliation(s)
- Geoffrey Schwertz
- Laboratorium für Organische Chemie; ETH Zurich; Vladimir-Prelog-Weg 3 8093 Zurich Switzerland
| | - Michelle S. Frei
- Laboratorium für Organische Chemie; ETH Zurich; Vladimir-Prelog-Weg 3 8093 Zurich Switzerland
| | | | - Matthias Rottmann
- Swiss Tropical and Public Health Institute (SwissTPHI); Socinstrasse 57 4051 Basel Switzerland
- Universität Basel; Petersplatz 1 4003 Basel Switzerland
| | - Ubolsree Leartsakulpanich
- National Center for Genetic Engineering and Biotechnology; 113 Thailand Science Park, Phahonyothin Road Pathumthani 12120 Thailand
| | - Penchit Chitnumsub
- National Center for Genetic Engineering and Biotechnology; 113 Thailand Science Park, Phahonyothin Road Pathumthani 12120 Thailand
| | - Aritsara Jaruwat
- National Center for Genetic Engineering and Biotechnology; 113 Thailand Science Park, Phahonyothin Road Pathumthani 12120 Thailand
| | - Wanwipa Ittarat
- National Center for Genetic Engineering and Biotechnology; 113 Thailand Science Park, Phahonyothin Road Pathumthani 12120 Thailand
| | - Anja Schäfer
- Swiss Tropical and Public Health Institute (SwissTPHI); Socinstrasse 57 4051 Basel Switzerland
- Universität Basel; Petersplatz 1 4003 Basel Switzerland
| | | | - Nils Trapp
- Laboratorium für Organische Chemie; ETH Zurich; Vladimir-Prelog-Weg 3 8093 Zurich Switzerland
| | - Kerstin Mark
- Laboratorium für Organische Chemie; ETH Zurich; Vladimir-Prelog-Weg 3 8093 Zurich Switzerland
| | - Pimchai Chaiyen
- Department of Biochemistry and Center for Excellence in Protein and Enzyme Technology; Faculty of Science Mahidol University; 272 Rama VI Road Bangkok 10400 Thailand
- Department of Biomolecular Science and Engineering; School of Biomolecular Science & Engineering; Vidyasirimedhi Institute of Science and Technology (VISTEC), Wangchan Valley; Rayong 21210 Thailand
| | - François Diederich
- Laboratorium für Organische Chemie; ETH Zurich; Vladimir-Prelog-Weg 3 8093 Zurich Switzerland
| |
Collapse
|
22
|
Schwertz G, Witschel MC, Rottmann M, Bonnert R, Leartsakulpanich U, Chitnumsub P, Jaruwat A, Ittarat W, Schäfer A, Aponte RA, Charman SA, White KL, Kundu A, Sadhukhan S, Lloyd M, Freiberg GM, Srikumaran M, Siggel M, Zwyssig A, Chaiyen P, Diederich F. Antimalarial Inhibitors Targeting Serine Hydroxymethyltransferase (SHMT) with in Vivo Efficacy and Analysis of their Binding Mode Based on X-ray Cocrystal Structures. J Med Chem 2017; 60:4840-4860. [DOI: 10.1021/acs.jmedchem.7b00008] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Geoffrey Schwertz
- Laboratorium für
Organische Chemie, ETH Zurich, Vladimir-Prelog-Weg 3, 8093 Zurich, Switzerland
| | | | - Matthias Rottmann
- Swiss Tropical and Public Health Institute (SwissTPH), Socinstrasse
57, 4051 Basel, Switzerland
- Universität Basel, Petersplatz 1, 4003 Basel, Switzerland
| | - Roger Bonnert
- Medicines for Malaria Venture, Route de Pré-Bois 20, CH-1215 Geneva, Switzerland
| | - Ubolsree Leartsakulpanich
- National Center for Genetic Engineering and Biotechnology, 113 Thailand Science Park, Phahonyothin Road, Pathumthni 12120, Thailand
| | - Penchit Chitnumsub
- National Center for Genetic Engineering and Biotechnology, 113 Thailand Science Park, Phahonyothin Road, Pathumthni 12120, Thailand
| | - Aritsara Jaruwat
- National Center for Genetic Engineering and Biotechnology, 113 Thailand Science Park, Phahonyothin Road, Pathumthni 12120, Thailand
| | - Wanwipa Ittarat
- National Center for Genetic Engineering and Biotechnology, 113 Thailand Science Park, Phahonyothin Road, Pathumthni 12120, Thailand
| | - Anja Schäfer
- Swiss Tropical and Public Health Institute (SwissTPH), Socinstrasse
57, 4051 Basel, Switzerland
- Universität Basel, Petersplatz 1, 4003 Basel, Switzerland
| | | | - Susan A. Charman
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Karen L. White
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Abhijit Kundu
- TCG Lifesciences Private Limited, Block BN, Plot 7, Saltlake Electronics Complex, Sector V, Kolkata 700091, West Bengal India
| | - Surajit Sadhukhan
- TCG Lifesciences Private Limited, Block BN, Plot 7, Saltlake Electronics Complex, Sector V, Kolkata 700091, West Bengal India
| | - Mel Lloyd
- Covance Laboratories Ltd., Otley Road, Harrogate HG3 1PY, United Kingdom
| | - Gail M. Freiberg
- Molecular
Characterization, Department R4AE, AbbVie, 1 North Waukegan Road, North Chicago, Illinois 60064-6217, United States
| | - Myron Srikumaran
- Molecular
Characterization, Department R4AE, AbbVie, 1 North Waukegan Road, North Chicago, Illinois 60064-6217, United States
| | - Marc Siggel
- Laboratorium für
Organische Chemie, ETH Zurich, Vladimir-Prelog-Weg 3, 8093 Zurich, Switzerland
| | - Adrian Zwyssig
- Laboratorium für
Organische Chemie, ETH Zurich, Vladimir-Prelog-Weg 3, 8093 Zurich, Switzerland
| | - Pimchai Chaiyen
- Department of
Biochemistry and Center for Excellence in Protein and Enzyme Technology, Faculty of Science Mahidol University, 272 Rama VI Road, Bangkok 10400, Thailand
| | - François Diederich
- Laboratorium für
Organische Chemie, ETH Zurich, Vladimir-Prelog-Weg 3, 8093 Zurich, Switzerland
| |
Collapse
|
23
|
Najer A, Wu D, Nussbaumer MG, Schwertz G, Schwab A, Witschel MC, Schäfer A, Diederich F, Rottmann M, Palivan CG, Beck HP, Meier W. An amphiphilic graft copolymer-based nanoparticle platform for reduction-responsive anticancer and antimalarial drug delivery. Nanoscale 2016; 8:14858-69. [PMID: 27452350 DOI: 10.1039/c6nr04290b] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
Medical applications of anticancer and antimalarial drugs often suffer from low aqueous solubility, high systemic toxicity, and metabolic instability. Smart nanocarrier-based drug delivery systems provide means of solving these problems at once. Herein, we present such a smart nanoparticle platform based on self-assembled, reduction-responsive amphiphilic graft copolymers, which were successfully synthesized through thiol-disulfide exchange reaction between thiolated hydrophilic block and pyridyl disulfide functionalized hydrophobic block. These amphiphilic graft copolymers self-assembled into nanoparticles with mean diameters of about 30-50 nm and readily incorporated hydrophobic guest molecules. Fluorescence correlation spectroscopy (FCS) was used to study nanoparticle stability and triggered release of a model compound in detail. Long-term colloidal stability and model compound retention within the nanoparticles was found when analyzed in cell media at body temperature. In contrast, rapid, complete reduction-triggered disassembly and model compound release was achieved within a physiological reducing environment. The synthesized copolymers revealed no intrinsic cellular toxicity up to 1 mg mL(-1). Drug-loaded reduction-sensitive nanoparticles delivered a hydrophobic model anticancer drug (doxorubicin, DOX) to cancer cells (HeLa cells) and an experimental, metabolically unstable antimalarial drug (the serine hydroxymethyltransferase (SHMT) inhibitor (±)-1) to Plasmodium falciparum-infected red blood cells (iRBCs), with higher efficacy compared to similar, non-sensitive drug-loaded nanoparticles. These responsive copolymer-based nanoparticles represent a promising candidate as smart nanocarrier platform for various drugs to be applied to different diseases, due to the biocompatibility and biodegradability of the hydrophobic block, and the protein-repellent hydrophilic block.
Collapse
Affiliation(s)
- Adrian Najer
- Department of Chemistry, University of Basel, Klingelbergstrasse 80, CH-4056 Basel, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Bürstner N, Roggo S, Ostermann N, Blank J, Delmas C, Freuler F, Gerhartz B, Hinniger A, Hoepfner D, Liechty B, Mihalic M, Murphy J, Pistorius D, Rottmann M, Thomas JR, Schirle M, Schmitt EK. Inside Cover: Gift from Nature: Cyclomarin A Kills Mycobacteria and Malaria Parasites by Distinct Modes of Action (ChemBioChem 17/2015). Chembiochem 2015. [DOI: 10.1002/cbic.201500579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Nathalie Bürstner
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Silvio Roggo
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Nils Ostermann
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Jutta Blank
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Cecile Delmas
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Felix Freuler
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Bernd Gerhartz
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Alexandra Hinniger
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Dominic Hoepfner
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Brigitta Liechty
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Manuel Mihalic
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Jason Murphy
- Novartis Institutes for BioMedical Research Inc; 250 Massachusetts Avenue Cambridge MA 02139 USA
| | - Dominik Pistorius
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Matthias Rottmann
- Swiss Tropical and Public Health Institute; Socinstrasse 57 4051 Basel Switzerland
| | - Jason R. Thomas
- Novartis Institutes for BioMedical Research Inc; 250 Massachusetts Avenue Cambridge MA 02139 USA
| | - Markus Schirle
- Novartis Institutes for BioMedical Research Inc; 250 Massachusetts Avenue Cambridge MA 02139 USA
| | - Esther K. Schmitt
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| |
Collapse
|
25
|
Bürstner N, Roggo S, Ostermann N, Blank J, Delmas C, Freuler F, Gerhartz B, Hinniger A, Hoepfner D, Liechty B, Mihalic M, Murphy J, Pistorius D, Rottmann M, Thomas JR, Schirle M, Schmitt EK. Gift from Nature: Cyclomarin A Kills Mycobacteria and Malaria Parasites by Distinct Modes of Action. Chembiochem 2015; 16:2433-6. [DOI: 10.1002/cbic.201500472] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2015] [Indexed: 11/11/2022]
Affiliation(s)
- Nathalie Bürstner
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Silvio Roggo
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Nils Ostermann
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Jutta Blank
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Cecile Delmas
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Felix Freuler
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Bernd Gerhartz
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Alexandra Hinniger
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Dominic Hoepfner
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Brigitta Liechty
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Manuel Mihalic
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Jason Murphy
- Novartis Institutes for BioMedical Research Inc; 250 Massachusetts Avenue Cambridge MA 02139 USA
| | - Dominik Pistorius
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| | - Matthias Rottmann
- Swiss Tropical and Public Health Institute; Socinstrasse 57 4051 Basel Switzerland
| | - Jason R. Thomas
- Novartis Institutes for BioMedical Research Inc; 250 Massachusetts Avenue Cambridge MA 02139 USA
| | - Markus Schirle
- Novartis Institutes for BioMedical Research Inc; 250 Massachusetts Avenue Cambridge MA 02139 USA
| | - Esther K. Schmitt
- Novartis Institutes for BioMedical Research; Novartis Campus 4056 Basel Switzerland
| |
Collapse
|
26
|
Brancucci NMB, Bertschi NL, Zhu L, Niederwieser I, Chin WH, Wampfler R, Freymond C, Rottmann M, Felger I, Bozdech Z, Voss TS. Heterochromatin protein 1 secures survival and transmission of malaria parasites. Cell Host Microbe 2015; 16:165-176. [PMID: 25121746 DOI: 10.1016/j.chom.2014.07.004] [Citation(s) in RCA: 177] [Impact Index Per Article: 19.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2014] [Revised: 04/28/2014] [Accepted: 06/06/2014] [Indexed: 12/14/2022]
Abstract
Clonally variant expression of surface antigens allows the malaria parasite Plasmodium falciparum to evade immune recognition during blood stage infection and secure malaria transmission. We demonstrate that heterochromatin protein 1 (HP1), an evolutionary conserved regulator of heritable gene silencing, controls expression of numerous P. falciparum virulence genes as well as differentiation into the sexual forms that transmit to mosquitoes. Conditional depletion of P. falciparum HP1 (PfHP1) prevents mitotic proliferation of blood stage parasites and disrupts mutually exclusive expression and antigenic variation of the major virulence factor PfEMP1. Additionally, PfHP1-dependent regulation of PfAP2-G, a transcription factor required for gametocyte conversion, controls the switch from asexual proliferation to sexual differentiation, providing insight into the epigenetic mechanisms underlying gametocyte commitment. These findings show that PfHP1 is centrally involved in clonally variant gene expression and sexual differentiation in P. falciparum and have major implications for developing antidisease and transmission-blocking interventions against malaria.
Collapse
Affiliation(s)
- Nicolas M B Brancucci
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel 4051, Switzerland; University of Basel, Petersplatz 1, Basel 4003, Switzerland
| | - Nicole L Bertschi
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel 4051, Switzerland; University of Basel, Petersplatz 1, Basel 4003, Switzerland
| | - Lei Zhu
- School of Biological Sciences, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798, Singapore
| | - Igor Niederwieser
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel 4051, Switzerland; University of Basel, Petersplatz 1, Basel 4003, Switzerland
| | - Wai Hoe Chin
- School of Biological Sciences, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798, Singapore
| | - Rahel Wampfler
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel 4051, Switzerland; University of Basel, Petersplatz 1, Basel 4003, Switzerland
| | - Céline Freymond
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel 4051, Switzerland; University of Basel, Petersplatz 1, Basel 4003, Switzerland
| | - Matthias Rottmann
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel 4051, Switzerland; University of Basel, Petersplatz 1, Basel 4003, Switzerland
| | - Ingrid Felger
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel 4051, Switzerland; University of Basel, Petersplatz 1, Basel 4003, Switzerland
| | - Zbynek Bozdech
- School of Biological Sciences, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798, Singapore
| | - Till S Voss
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel 4051, Switzerland; University of Basel, Petersplatz 1, Basel 4003, Switzerland.
| |
Collapse
|
27
|
Witschel MC, Rottmann M, Schwab A, Leartsakulpanich U, Chitnumsub P, Seet M, Tonazzi S, Schwertz G, Stelzer F, Mietzner T, McNamara C, Thater F, Freymond C, Jaruwat A, Pinthong C, Riangrungroj P, Oufir M, Hamburger M, Mäser P, Sanz-Alonso LM, Charman S, Wittlin S, Yuthavong Y, Chaiyen P, Diederich F. Inhibitors of Plasmodial Serine Hydroxymethyltransferase (SHMT): Cocrystal Structures of Pyrazolopyrans with Potent Blood- and Liver-Stage Activities. J Med Chem 2015; 58:3117-30. [DOI: 10.1021/jm501987h] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
| | - Matthias Rottmann
- Swiss Tropical and Public Health Institute (Swiss TPH), Socinstrasse 57, 4051 Basel, Switzerland
- Universität Basel, Petersplatz 1, 4003 Basel, Switzerland
| | - Anatol Schwab
- Laboratorium
für Organische Chemie, ETH Zurich, Vladimir-Prelog-Weg 3, 8093 Zurich, Switzerland
| | - Ubolsree Leartsakulpanich
- National Center for Genetic Engineering and Biotechnology, 113 Thailand Science Park, Phahonyothin Road, Khlong Nueng, Khlong Luang, Pathum Thani 12120, Thailand
| | - Penchit Chitnumsub
- National Center for Genetic Engineering and Biotechnology, 113 Thailand Science Park, Phahonyothin Road, Khlong Nueng, Khlong Luang, Pathum Thani 12120, Thailand
| | - Michael Seet
- Laboratorium
für Organische Chemie, ETH Zurich, Vladimir-Prelog-Weg 3, 8093 Zurich, Switzerland
| | - Sandro Tonazzi
- Laboratorium
für Organische Chemie, ETH Zurich, Vladimir-Prelog-Weg 3, 8093 Zurich, Switzerland
| | - Geoffrey Schwertz
- Laboratorium
für Organische Chemie, ETH Zurich, Vladimir-Prelog-Weg 3, 8093 Zurich, Switzerland
| | - Frank Stelzer
- BASF SE, Carl-Bosch-Strasse
38, 67056 Ludwigshafen, Germany
| | | | - Case McNamara
- California Institute for Biomedical Research (Calibr), 11119 North Torrey Pines Road, Suite 100, La Jolla, California 92037, United States
| | - Frank Thater
- BASF SE, Carl-Bosch-Strasse
38, 67056 Ludwigshafen, Germany
| | - Céline Freymond
- Swiss Tropical and Public Health Institute (Swiss TPH), Socinstrasse 57, 4051 Basel, Switzerland
- Universität Basel, Petersplatz 1, 4003 Basel, Switzerland
| | - Aritsara Jaruwat
- National Center for Genetic Engineering and Biotechnology, 113 Thailand Science Park, Phahonyothin Road, Khlong Nueng, Khlong Luang, Pathum Thani 12120, Thailand
| | - Chatchadaporn Pinthong
- Department
of Biochemistry and Center of Excellence in Protein Structure and
Function, Faculty of Science, Mahidol University, 272 Rama VI Road, Bangkok 10400, Thailand
| | - Pinpunya Riangrungroj
- National Center for Genetic Engineering and Biotechnology, 113 Thailand Science Park, Phahonyothin Road, Khlong Nueng, Khlong Luang, Pathum Thani 12120, Thailand
| | - Mouhssin Oufir
- Pharmaceutical
Biology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Matthias Hamburger
- Pharmaceutical
Biology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
| | - Pascal Mäser
- Swiss Tropical and Public Health Institute (Swiss TPH), Socinstrasse 57, 4051 Basel, Switzerland
- Universität Basel, Petersplatz 1, 4003 Basel, Switzerland
| | - Laura M. Sanz-Alonso
- Diseases of the
Developing World (DDW), GlaxoSmithKline, C. Severo Ochoa, 2, 28760 Tres Cantos, Spain
| | - Susan Charman
- Centre
for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Sergio Wittlin
- Swiss Tropical and Public Health Institute (Swiss TPH), Socinstrasse 57, 4051 Basel, Switzerland
- Universität Basel, Petersplatz 1, 4003 Basel, Switzerland
| | - Yongyuth Yuthavong
- National Center for Genetic Engineering and Biotechnology, 113 Thailand Science Park, Phahonyothin Road, Khlong Nueng, Khlong Luang, Pathum Thani 12120, Thailand
| | - Pimchai Chaiyen
- Department
of Biochemistry and Center of Excellence in Protein Structure and
Function, Faculty of Science, Mahidol University, 272 Rama VI Road, Bangkok 10400, Thailand
| | - François Diederich
- Laboratorium
für Organische Chemie, ETH Zurich, Vladimir-Prelog-Weg 3, 8093 Zurich, Switzerland
| |
Collapse
|
28
|
Schmalfeldt B, Burges A, Mayr D, Schubert-Fritschle G, Rottmann M, Engel J. Qualität der Therapie des Ovarialkarzinoms in der Region des Tumorzentrums München. Epidemiologische Daten im Vergleich. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
29
|
Reker D, Seet M, Pillong M, Koch CP, Schneider P, Witschel MC, Rottmann M, Freymond C, Brun R, Schweizer B, Illarionov B, Bacher A, Fischer M, Diederich F, Schneider G. Identifizierung von Pyrrolopyrazinen als polypotente Liganden mit Antimalariawirkung. Angew Chem Int Ed Engl 2014. [DOI: 10.1002/ange.201311162] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
30
|
Reker D, Seet M, Pillong M, Koch CP, Schneider P, Witschel MC, Rottmann M, Freymond C, Brun R, Schweizer B, Illarionov B, Bacher A, Fischer M, Diederich F, Schneider G. Deorphaning pyrrolopyrazines as potent multi-target antimalarial agents. Angew Chem Int Ed Engl 2014; 53:7079-84. [PMID: 24895172 DOI: 10.1002/anie.201311162] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Revised: 03/06/2014] [Indexed: 11/10/2022]
Abstract
The discovery of pyrrolopyrazines as potent antimalarial agents is presented, with the most effective compounds exhibiting EC50 values in the low nanomolar range against asexual blood stages of Plasmodium falciparum in human red blood cells, and Plasmodium berghei liver schizonts, with negligible HepG2 cytotoxicity. Their potential mode of action is uncovered by predicting macromolecular targets through avant-garde computer modeling. The consensus prediction method suggested a functional resemblance between ligand binding sites in non-homologous target proteins, linking the observed parasite elimination to IspD, an enzyme from the non-mevalonate pathway of isoprenoid biosynthesis, and multi-kinase inhibition. Further computational analysis suggested essential P. falciparum kinases as likely targets of our lead compound. The results obtained validate our methodology for ligand- and structure-based target prediction, expand the bioinformatics toolbox for proteome mining, and provide unique access to deciphering polypharmacological effects of bioactive chemical agents.
Collapse
Affiliation(s)
- Daniel Reker
- Departement Chemie und Angewandte Biowissenschaften, ETH Zürich, Vladimir-Prelog-Weg 3-4, 8093 Zürich (Switzerland)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Kunfermann A, Witschel M, Illarionov B, Martin R, Rottmann M, Höffken HW, Seet M, Eisenreich W, Knölker HJ, Fischer M, Bacher A, Groll M, Diederich F. Pseudiline: halogenierte, allosterische Inhibitoren des Enzyms IspD aus dem Mevalonat-unabhängigen Biosyntheseweg. Angew Chem Int Ed Engl 2014. [DOI: 10.1002/ange.201309557] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
32
|
Kunfermann A, Witschel M, Illarionov B, Martin R, Rottmann M, Höffken HW, Seet M, Eisenreich W, Knölker HJ, Fischer M, Bacher A, Groll M, Diederich F. Pseudilins: Halogenated, Allosteric Inhibitors of the Non-Mevalonate Pathway Enzyme IspD. Angew Chem Int Ed Engl 2014; 53:2235-9. [DOI: 10.1002/anie.201309557] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2013] [Revised: 12/15/2013] [Indexed: 01/10/2023]
|
33
|
Kemp LE, Rusch M, Adibekian A, Bullen HE, Graindorge A, Freymond C, Rottmann M, Braun-Breton C, Baumeister S, Porfetye AT, Vetter IR, Hedberg C, Soldati-Favre D. Characterization of a serine hydrolase targeted by acyl-protein thioesterase inhibitors in Toxoplasma gondii. J Biol Chem 2013; 288:27002-27018. [PMID: 23913689 DOI: 10.1074/jbc.m113.460709] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
In eukaryotic organisms, cysteine palmitoylation is an important reversible modification that impacts protein targeting, folding, stability, and interactions with partners. Evidence suggests that protein palmitoylation contributes to key biological processes in Apicomplexa with the recent palmitome of the malaria parasite Plasmodium falciparum reporting over 400 substrates that are modified with palmitate by a broad range of protein S-acyl transferases. Dynamic palmitoylation cycles require the action of an acyl-protein thioesterase (APT) that cleaves palmitate from substrates and conveys reversibility to this posttranslational modification. In this work, we identified candidates for APT activity in Toxoplasma gondii. Treatment of parasites with low micromolar concentrations of β-lactone- or triazole urea-based inhibitors that target human APT1 showed varied detrimental effects at multiple steps of the parasite lytic cycle. The use of an activity-based probe in combination with these inhibitors revealed the existence of several serine hydrolases that are targeted by APT1 inhibitors. The active serine hydrolase, TgASH1, identified as the homologue closest to human APT1 and APT2, was characterized further. Biochemical analysis of TgASH1 indicated that this enzyme cleaves substrates with a specificity similar to APTs, and homology modeling points toward an APT-like enzyme. TgASH1 is dispensable for parasite survival, which indicates that the severe effects observed with the β-lactone inhibitors are caused by the inhibition of non-TgASH1 targets. Other ASH candidates for APT activity were functionally characterized, and one of them was found to be resistant to gene disruption due to the potential essential nature of the protein.
Collapse
Affiliation(s)
- Louise E Kemp
- Department of Microbiology and Molecular Medicine, University Medical Center (CMU), University of Geneva, Rue Michel-Servet 1, CH-1211 Geneva, Switzerland
| | | | - Alexander Adibekian
- Department of Biochemistry, Sciences II, University of Geneva, Quai Ernest Ansermet 30, CH-1211 Geneva, Switzerland
| | - Hayley E Bullen
- Department of Microbiology and Molecular Medicine, University Medical Center (CMU), University of Geneva, Rue Michel-Servet 1, CH-1211 Geneva, Switzerland
| | - Arnault Graindorge
- Department of Microbiology and Molecular Medicine, University Medical Center (CMU), University of Geneva, Rue Michel-Servet 1, CH-1211 Geneva, Switzerland
| | - Céline Freymond
- Department of Parasite Chemotherapy, Swiss Tropical and Public Health Institute, Socinstrasse 57, P. O. Box, CH-4002 Basel, Switzerland; University of Basel, CH-4003 Basel, Switzerland
| | - Matthias Rottmann
- Department of Parasite Chemotherapy, Swiss Tropical and Public Health Institute, Socinstrasse 57, P. O. Box, CH-4002 Basel, Switzerland; University of Basel, CH-4003 Basel, Switzerland
| | | | - Stefan Baumeister
- Departments of Mechanistic Cell Biology, Max Planck Institute of Molecular Physiology, Otto-Hahn-Strasse 11, 44227 Dortmund, Germany
| | - Arthur T Porfetye
- Departments of Mechanistic Cell Biology, Max Planck Institute of Molecular Physiology, Otto-Hahn-Strasse 11, 44227 Dortmund, Germany
| | - Ingrid R Vetter
- Departments of Mechanistic Cell Biology, Max Planck Institute of Molecular Physiology, Otto-Hahn-Strasse 11, 44227 Dortmund, Germany
| | | | - Dominique Soldati-Favre
- Department of Microbiology and Molecular Medicine, University Medical Center (CMU), University of Geneva, Rue Michel-Servet 1, CH-1211 Geneva, Switzerland.
| |
Collapse
|
34
|
Ehmke V, Winkler E, Banner DW, Haap W, Schweizer WB, Rottmann M, Kaiser M, Freymond C, Schirmeister T, Diederich F. Optimization of triazine nitriles as rhodesain inhibitors: structure-activity relationships, bioisosteric imidazopyridine nitriles, and X-ray crystal structure analysis with human cathepsin L. ChemMedChem 2013; 8:967-75. [PMID: 23658062 DOI: 10.1002/cmdc.201300112] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Indexed: 11/10/2022]
Abstract
The cysteine protease rhodesain of Trypanosoma brucei parasites causing African sleeping sickness has emerged as a target for the development of new drug candidates. Based on a triazine nitrile moiety as electrophilic headgroup, optimization studies on the substituents for the S1, S2, and S3 pockets of the enzyme were performed using structure-based design and resulted in inhibitors with inhibition constants in the single-digit nanomolar range. Comprehensive structure-activity relationships clarified the binding preferences of the individual pockets of the active site. The S1 pocket tolerates various substituents with a preference for flexible and basic side chains. Variation of the S2 substituent led to high-affinity ligands with inhibition constants down to 2 nM for compounds bearing cyclohexyl substituents. Systematic investigations on the S3 pocket revealed its potential to achieve high activities with aromatic vectors that undergo stacking interactions with the planar peptide backbone forming part of the pocket. X-ray crystal structure analysis with the structurally related enzyme human cathepsin L confirmed the binding mode of the triazine ligand series as proposed by molecular modeling. Sub-micromolar inhibition of the proliferation of cultured parasites was achieved for ligands decorated with the best substituents identified through the optimization cycles. In cell-based assays, the introduction of a basic side chain on the inhibitors resulted in a 35-fold increase in antitrypanosomal activity. Finally, bioisosteric imidazopyridine nitriles were studied in order to prevent off-target effects with unselective nucleophiles by decreasing the inherent electrophilicity of the triazine nitrile headgroup. Using this ligand, the stabilization by intramolecular hydrogen bonding of the thioimidate intermediate, formed upon attack of the catalytic cysteine residue, compensates for the lower reactivity of the headgroup. The imidazopyridine nitrile ligand showed excellent stability toward the thiol nucleophile glutathione in a quantitative in vitro assay and fourfold lower cytotoxicity than the parent triazine nitrile.
Collapse
Affiliation(s)
- Veronika Ehmke
- Laboratorium für Organische Chemie, ETH Zürich, Zürich, Switzerland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Rottmann M, Mielck A. ['Walkability' and physical activity - results of empirical studies based on the 'Neighbourhood Environment Walkability Scale (NEWS)']. Gesundheitswesen 2013; 76:108-15. [PMID: 23572473 DOI: 10.1055/s-0033-1338000] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
OBJECTIVE 'Walkability' is mainly assessed by the NEWS questionnaire (Neighbourhood Environment Walkability Scale); in Germany this questionnaire is widely unknown. We now try to fill this gap by providing a systematic overview of empirical studies based on the NEWS. METHODS A systematic review was conducted concerning original papers including empirical analyses based on the NEWS. The results are summarised and presented in tables. RESULTS Altogether 31 publications could be identified. Most of them focus on associations with the variable 'physical activity', and they often report significant associations with at least some of the scales included in the NEWS. Due to methodological differences between the studies it is difficult to compare the results. CONCLUSION The concept of 'walkability' should also be established in the German public health discussion. A number of methodological challenges remain to be solved, such as the identification of those scales and items in the NEWS that show the strongest associations with individual health behaviours.
Collapse
Affiliation(s)
- M Rottmann
- Institut für Gesundheitsökonomie und Management im Gesundheitswesen, Helmholtz Zentrum München, Neuherberg
| | - A Mielck
- Institut für Gesundheitsökonomie und Management im Gesundheitswesen, Helmholtz Zentrum München, Neuherberg
| |
Collapse
|
36
|
Rottmann M, Maier W, von Klot S, Döring A, Mielck A. [Association between the social status of city districts and health risks: multilevel analyses concerning the regional distribution of overweight, hypertension and self-rated health in Augsburg, Germany]. Gesundheitswesen 2012; 75:134-9. [PMID: 23229162 DOI: 10.1055/s-0032-1327739] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
INTRODUCTION In empirical studies it has repeatedly been shown that the socioeconomic status (SES) of a region could infl uence the health status of its inhabitants, even if measures of individual SES are controlled for. This research has just started in Germany, but most studies focus on large geographical areas such as rural districts. Taking the example of districts in the city of Augsburg, the analyses focus on the question if these associations can also be found in a small-scale regional comparison. METHODS We included 1 888 participants of the KORA S4 Survey aged 25-74 years. The city districts were grouped according to the unemployment rate (low, medium, high). The dependent variables were self-rated health and 3 risk factors (obesity, high waist-hip ratio, hypertension). Additional individual variables included are age, sex, educational level and unemployment. The analyses were based on multilevel logistic regressions. RESULTS After adjustment for individual level variables (age, sex, education, unemployment), the analyses show a signifi cantly increased risk of 'high waist-hip ratio' in the regions with the highest unemployment rate (OR 1.53; 95 % conf. interval 1.03-2.26). A similar association was found for obesity. No signifi cant association was observed between unemployment rate on the one hand and hypertension and self-rated health on the other. CONCLUSION Some health risks seem to be especially high in city districts characterised by a high unemployment rate. It can be concluded that interventions aimed at reducing these risks should focus on districts with high unemployment rates. Further studies are needed for an understanding of the causes behind the social and regional inequalities shown here.
Collapse
Affiliation(s)
- M Rottmann
- Institut für Gesundheitsökonomie und Management im Gesundheitswesen, Helmholtz Zentrum München, Deutsches Forschungszentrum für Umwelt und Gesundheit (GmbH), Neuherberg, Germany.
| | | | | | | | | |
Collapse
|
37
|
Aureggi V, Ehmke V, Wieland J, Schweizer WB, Bernet B, Bur D, Meyer S, Rottmann M, Freymond C, Brun R, Breit B, Diederich F. Potent inhibitors of malarial aspartic proteases, the plasmepsins, by hydroformylation of substituted 7-azanorbornenes. Chemistry 2012; 19:155-64. [PMID: 23161835 DOI: 10.1002/chem.201202941] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2012] [Indexed: 12/23/2022]
Abstract
The increasing prevalence of multidrug-resistant strains of the malarial parasite Plasmodium falciparum requires the urgent development of new therapeutic agents with novel modes of action. The vacuolar malarial aspartic proteases plasmepsin (PM) I, II, and IV are involved in hemoglobin degradation and play a central role in the growth and maturation of the parasite in the human host. We report the structure-based design, synthesis, and in vitro evaluation of a new generation of PM inhibitors featuring a highly decorated 7-azabicyclo[2.2.1]heptane core. While this protonated central core addresses the catalytic Asp dyad, three substituents bind to the flap, the S1/S3, and the S1' pockets of the enzymes. A hydroformylation reaction is the key synthetic step for the introduction of the new vector reaching into the S1' pocket. The configuration of the racemic ligands was confirmed by extensive NMR and X-ray crystallographic analysis. In vitro biological assays revealed high potency of the new inhibitors against the three plasmepsins (IC(50) values down to 6 nM) and good selectivity towards the closely related human cathepsins D and E. The occupancy of the S1' pocket makes an essential contribution to the gain in binding affinity and selectivity, which is particularly large in the case of the PM IV enzyme. Designing non-peptidic ligands for PM II is a valid route to generate compounds that inhibit the entire family of vacuolar plasmepsins.
Collapse
Affiliation(s)
- Valentina Aureggi
- Laboratorium für Organische Chemie, ETH Zurich, Hönggerberg HCI, 8093 Zurich, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Witschel M, Rottmann M, Kaiser M, Brun R. Agrochemicals against malaria, sleeping sickness, leishmaniasis and Chagas disease. PLoS Negl Trop Dis 2012; 6:e1805. [PMID: 23145187 PMCID: PMC3493374 DOI: 10.1371/journal.pntd.0001805] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2012] [Accepted: 07/18/2012] [Indexed: 12/30/2022] Open
Abstract
In tropical regions, protozoan parasites can cause severe diseases with malaria, leishmaniasis, sleeping sickness, and Chagas disease standing in the forefront. Many of the drugs currently being used to treat these diseases have been developed more than 50 years ago and can cause severe adverse effects. Above all, resistance to existing drugs is widespread and has become a serious problem threatening the success of control measures. In order to identify new antiprotozoal agents, more than 600 commercial agrochemicals have been tested on the pathogens causing the above mentioned diseases. For all of the pathogens, compounds were identified with similar or even higher activities than the currently used drugs in applied in vitro assays. Furthermore, in vivo activity was observed for the fungicide/oomyceticide azoxystrobin, and the insecticide hydramethylnon in the Plasmodium berghei mouse model, and for the oomyceticide zoxamide in the Trypanosoma brucei rhodesiense STIB900 mouse model, respectively. Even though agrochemistry and infectious disease control have the same principle goal – the suppression of harmful organisms without harming human health and the environment – there have been only very limited activities to exploit this overlap for the development of new antiinfectious drugs so far. In this study and for the first time, over 600 commercial agrochemicals were systematically screened against the infectious pathogens causing malaria, sleeping sickness, Chagas disease and leishmaniasis. Many highly active compounds with known low mammalian toxicity were identified in cell based assays, and the activity of some of them could even be confirmed in first animal model studies. Further expansion of this concept to other pathogens and the examination of analogues of the identified hits, potentially available from agrochemical companies, would allow for a very efficient source of novel drug candidates.
Collapse
Affiliation(s)
- Matthias Witschel
- BASF SE, Global Research Herbicides, Ludwigshafen, Germany
- * E-mail: (MW); (RB)
| | - Matthias Rottmann
- Swiss Tropical and Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
| | - Marcel Kaiser
- Swiss Tropical and Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
| | - Reto Brun
- Swiss Tropical and Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
- * E-mail: (MW); (RB)
| |
Collapse
|
39
|
Mäser P, Wittlin S, Rottmann M, Wenzler T, Kaiser M, Brun R. Antiparasitic agents: new drugs on the horizon. Curr Opin Pharmacol 2012; 12:562-6. [DOI: 10.1016/j.coph.2012.05.001] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2012] [Accepted: 05/03/2012] [Indexed: 11/29/2022]
|
40
|
Gemma S, Camodeca C, Sanna Coccone S, Joshi BP, Bernetti M, Moretti V, Brogi S, Bonache de Marcos MC, Savini L, Taramelli D, Basilico N, Parapini S, Rottmann M, Brun R, Lamponi S, Caccia S, Guiso G, Summers RL, E. Martin R, Saponara S, Gorelli B, Novellino E, Campiani G, Butini S. Optimization of 4-Aminoquinoline/Clotrimazole-Based Hybrid Antimalarials: Further Structure–Activity Relationships, in Vivo Studies, and Preliminary Toxicity Profiling. J Med Chem 2012; 55:6948-67. [DOI: 10.1021/jm300802s] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Sandra Gemma
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Caterina Camodeca
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Salvatore Sanna Coccone
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Bhupendra P. Joshi
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Matteo Bernetti
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Vittoria Moretti
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Simone Brogi
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | | | - Luisa Savini
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Donatella Taramelli
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
- Dipartimento
di Scienze Farmacologiche
e Biomolecolari, Università degli Studi di Milano, Via Balzaretti 9, 20133 Milano, Italy
| | - Nicoletta Basilico
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
- Dipartimento di Scienze Biomediche,
Chirurgiche e Odontoiatriche, Università degli Studi di Milano, Via Pascal 36, 20133 Milano, Italy
| | - Silvia Parapini
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
- Dipartimento
di Scienze Farmacologiche
e Biomolecolari, Università degli Studi di Milano, Via Balzaretti 9, 20133 Milano, Italy
| | - Matthias Rottmann
- Swiss Tropical and Public Health Institute, Socinstrasse 57, CH-4002 Basel,
Switzerland and University of Basel, CH-4003 Basel, Switzerland
| | - Reto Brun
- Swiss Tropical and Public Health Institute, Socinstrasse 57, CH-4002 Basel,
Switzerland and University of Basel, CH-4003 Basel, Switzerland
| | - Stefania Lamponi
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Silvio Caccia
- Istituto di Ricerche Farmacologiche “Mario Negri”, Via la Masa
19, 20156 Milano, Italy
| | - Giovanna Guiso
- Istituto di Ricerche Farmacologiche “Mario Negri”, Via la Masa
19, 20156 Milano, Italy
| | - Robert L. Summers
- Research School of Biology, The Australian National University, Canberra ACT 0200,
Australia
| | - Rowena E. Martin
- Research School of Biology, The Australian National University, Canberra ACT 0200,
Australia
| | - Simona Saponara
- Dipartimento di
Neuroscienze, University of Siena, via
A. Moro, 53100, Siena, Italy
| | - Beatrice Gorelli
- Dipartimento di
Neuroscienze, University of Siena, via
A. Moro, 53100, Siena, Italy
| | - Ettore Novellino
- Dipartimento di Chimica Farmaceutica
e Tossicologica, Università di Napoli Federico II, Via D. Montesano 49, 80131 Napoli, Italy
| | - Giuseppe Campiani
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| | - Stefania Butini
- CIRM Centro Interuniversitario
di Ricerche sulla Malaria, Università di Torino, Torino, Italy
| |
Collapse
|
41
|
Mugasa J, Qi W, Rusch S, Rottmann M, Beck HP. Genetic diversity of expressed Plasmodium falciparum var genes from Tanzanian children with severe malaria. Malar J 2012; 11:230. [PMID: 22799500 PMCID: PMC3488018 DOI: 10.1186/1475-2875-11-230] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2012] [Accepted: 07/02/2012] [Indexed: 11/17/2022] Open
Abstract
Background Severe malaria has been attributed to the expression of a restricted subset of the var multi-gene family, which encodes for Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). PfEMP1 mediates cytoadherence and sequestration of infected erythrocytes into the post-capillary venules of vital organs such as the brain, lung or placenta. var genes are highly diverse and can be classified in three major groups (ups A, B and C) and two intermediate groups (B/A and B/C) based on the genomic location, gene orientation and upstream sequences. The genetic diversity of expressed var genes in relation to severity of disease in Tanzanian children was analysed. Methods Children with defined severe (SM) and asymptomatic malaria (AM) were recruited. Full-length var mRNA was isolated and reversed transcribed into var cDNA. Subsequently, the DBL and N-terminal domains, and up-stream sequences were PCR amplified, cloned and sequenced. Sequences derived from SM and AM isolates were compared and analysed. Results The analysis confirmed that the var family is highly diverse in natural Plasmodium falciparum populations. Sequence diversity of amplified var DBL-1α and upstream regions showed minimal overlap among isolates, implying that the var gene repertoire is vast and most probably indefinite in endemic areas. var DBL-1α sequences from AM isolates were more diverse with more singletons found (p<0.05) than those from SM infections. Furthermore, few var DBL-1α sequences from SM patients were rare and restricted suggesting that certain PfEMP1 variants might induce severe disease. Conclusions The genetic sequence diversity of var genes of P. falciparum isolates from Tanzanian children is large and its relationship to disease severity has been studied. Observed differences suggest that different var genes might have fundamentally different roles in the host-parasite interaction. Further research is required to examine clear disease-associations of var gene subsets in different geographical settings. The importance of very strict clinical definitions and appropriate large control groups needs to be emphasized for future studies on disease associations of PfEMP1.
Collapse
|
42
|
Nagle A, Wu T, Kuhen K, Gagaring K, Borboa R, Francek C, Chen Z, Plouffe D, Lin X, Caldwell C, Ek J, Skolnik S, Liu F, Wang J, Chang J, Li C, Liu B, Hollenbeck T, Tuntland T, Isbell J, Chuan T, Alper PB, Fischli C, Brun R, Lakshminarayana SB, Rottmann M, Diagana TT, Winzeler EA, Glynne R, Tully DC, Chatterjee AK. Imidazolopiperazines: lead optimization of the second-generation antimalarial agents. J Med Chem 2012; 55:4244-73. [PMID: 22524250 PMCID: PMC3350218 DOI: 10.1021/jm300041e] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
On the basis of the initial success of optimization of a novel series of imidazolopiperazines, a second generation of compounds involving changes in the core piperazine ring was synthesized to improve antimalarial properties. These changes were carried out to further improve the potency and metabolic stability of the compounds by leveraging the outcome of a set of in vitro metabolic identification studies. The optimized 8,8-dimethyl imidazolopiperazine analogues exhibited improved potency, in vitro metabolic stability profile and, as a result, enhanced oral exposure in vivo in mice. The optimized compounds were found to be more efficacious than the current antimalarials in a malaria mouse model. They exhibit moderate oral exposure in rat pharmacokinetic studies to achieve sufficient multiples of the oral exposure at the efficacious dose in toxicology studies.
Collapse
Affiliation(s)
- Advait Nagle
- Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Ehmke V, Quinsaat JEQ, Rivera-Fuentes P, Heindl C, Freymond C, Rottmann M, Brun R, Schirmeister T, Diederich F. Tuning and predicting biological affinity: aryl nitriles as cysteine protease inhibitors. Org Biomol Chem 2012; 10:5764-8. [DOI: 10.1039/c2ob00034b] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
44
|
Tripathi A, Puddick J, Prinsep MR, Rottmann M, Chan KP, Chen DYK, Tan LT. Lagunamide C, a cytotoxic cyclodepsipeptide from the marine cyanobacterium Lyngbya majuscula. Phytochemistry 2011; 72:2369-2375. [PMID: 21903231 DOI: 10.1016/j.phytochem.2011.08.019] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/16/2011] [Revised: 07/13/2011] [Accepted: 08/16/2011] [Indexed: 05/31/2023]
Abstract
Lagunamide C (1) is a cytotoxic cyclodepsipeptide isolated from the marine cyanobacterium, Lyngbya majuscula, from the western lagoon of Pulau Hantu Besar, Singapore. The complete structural characterization of the molecule was achieved by extensive NMR spectroscopic analysis as well as chemical manipulations. Several methods, including the advanced Marfey's method, a modified method based on derivatization with Mosher's reagents and analysis using LC-MS, and the use of (3)J(H-H) coupling constant values, were utilized for the determination of its absolute configuration. Compound 1 is related to the aurilide-class of molecules and it differs mainly in the macrocyclic structure by having a 27 membered ring system due to additional methylene carbon in the polyketide moiety. Lagunamide C displayed potent cytotoxic activity against a panel of cancer cell lines, such as P388, A549, PC3, HCT8, and SK-OV3 cell lines, with IC(50) values ranging from 2.1 nM to 24.4 nM. Compound 1 also displayed significant antimalarial activity with IC(50) value of 0.29 μM when tested against Plasmodium falciparum. In addition, lagunamide C exhibited weak anti-swarming activity when tested at 100 ppm against the Gram-negative bacterial strain, Pseudomonas aeruginosa PA01.
Collapse
Affiliation(s)
- Ashootosh Tripathi
- Natural Sciences and Science Education, National Institute of Education, Nanyang Technological University, Singapore, Singapore
| | | | | | | | | | | | | |
Collapse
|
45
|
Meister S, Plouffe DM, Kuhen KL, Bonamy GMC, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MCS, McNamara CW, Fidock DA, Nagle A, Nam TG, Richmond W, Roland J, Rottmann M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT, Winzeler EA. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 2011; 334:1372-7. [PMID: 22096101 DOI: 10.1126/science.1211936] [Citation(s) in RCA: 252] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Most malaria drug development focuses on parasite stages detected in red blood cells, even though, to achieve eradication, next-generation drugs active against both erythrocytic and exo-erythrocytic forms would be preferable. We applied a multifactorial approach to a set of >4000 commercially available compounds with previously demonstrated blood-stage activity (median inhibitory concentration < 1 micromolar) and identified chemical scaffolds with potent activity against both forms. From this screen, we identified an imidazolopiperazine scaffold series that was highly enriched among compounds active against Plasmodium liver stages. The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity. The open-source chemical tools resulting from our effort provide starting points for future drug discovery programs, as well as opportunities for researchers to investigate the biology of exo-erythrocytic forms.
Collapse
Affiliation(s)
- Stephan Meister
- Department of Genetics, The Scripps Research Institute, La Jolla, CA 92037, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Mombelli P, Witschel MC, van Zijl AW, Geist JG, Rottmann M, Freymond C, Röhl F, Kaiser M, Illarionova V, Fischer M, Siepe I, Schweizer WB, Brun R, Diederich F. Identification of 1,3-Diiminoisoindoline Carbohydrazides as Potential Antimalarial Candidates. ChemMedChem 2011; 7:151-8. [DOI: 10.1002/cmdc.201100441] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2011] [Revised: 10/25/2011] [Indexed: 12/15/2022]
|
47
|
Wu T, Nagle A, Kuhen K, Gagaring K, Borboa R, Francek C, Chen Z, Plouffe D, Goh A, Lakshminarayana SB, Wu J, Ang HQ, Zeng P, Kang ML, Tan W, Tan M, Ye N, Lin X, Caldwell C, Ek J, Skolnik S, Liu F, Wang J, Chang J, Li C, Hollenbeck T, Tuntland T, Isbell J, Fischli C, Brun R, Rottmann M, Dartois V, Keller T, Diagana T, Winzeler E, Glynne R, Tully DC, Chatterjee AK. Imidazolopiperazines: hit to lead optimization of new antimalarial agents. J Med Chem 2011; 54:5116-30. [PMID: 21644570 PMCID: PMC6950218 DOI: 10.1021/jm2003359] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
![]()
Starting from a hit series from a GNF compound library collection and based on a cell-based proliferation assay of Plasmodium falciparum, a novel imidazolopiperazine scaffold was optimized. SAR for this series of compounds is discussed, focusing on optimization of cellular potency against wild-type and drug resistant parasites and improvement of physiochemical and pharmacokinetic properties. The lead compounds in this series showed good potencies in vitro and decent oral exposure levels in vivo. In a Plasmodium berghei mouse infection model, one lead compound lowered the parasitemia level by 99.4% after administration of 100 mg/kg single oral dose and prolonged mice survival by an average of 17.0 days. The lead compounds were also well-tolerated in the preliminary in vitro toxicity studies and represents an interesting lead for drug development.
Collapse
Affiliation(s)
- Tao Wu
- Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Chadwick J, Amewu RK, Marti F, Garah FBE, Sharma R, Berry NG, Stocks PA, Burrell-Saward H, Wittlin S, Rottmann M, Brun R, Taramelli D, Parapini S, Ward SA, O'Neill PM. Antimalarial Mannoxanes: Hybrid Antimalarial Drugs with Outstanding Oral Activity Profiles and A Potential Dual Mechanism of Action. ChemMedChem 2011; 6:1357-61. [DOI: 10.1002/cmdc.201100196] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2011] [Indexed: 11/11/2022]
|
49
|
Tripathi A, Puddick J, Prinsep MR, Rottmann M, Tan LT. Lagunamides A and B: cytotoxic and antimalarial cyclodepsipeptides from the marine cyanobacterium Lyngbya majuscula. J Nat Prod 2010; 73:1810-4. [PMID: 20936843 DOI: 10.1021/np100442x] [Citation(s) in RCA: 89] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
Lagunamides A (1) and B (2) are new cyclic depsipeptides isolated from the marine cyanobacterium Lyngbya majuscula obtained from Pulau Hantu Besar, Singapore. The planar structural characterization of these molecules was achieved by extensive spectroscopic analysis, including 2D NMR experiments. In addition to Marfey's method and (3)J(H-H) coupling constant values, a modified method based on Mosher's reagents and analysis using LC-MS was deployed for the determination of the absolute configuration. Lagunamides A and B displayed significant antimalarial properties, with IC(50) values of 0.19 and 0.91 μM, respectively, when tested against Plasmodium falciparum. Lagunamides A and B also possessed potent cytotoxic activity against P388 murine leukemia cell lines, with IC(50) values of 6.4 and 20.5 nM, respectively. Furthermore, these cyanobacterial compounds exhibited moderate antiswarming activities when tested against Pseudomonas aeruginosa PA01.
Collapse
Affiliation(s)
- Ashootosh Tripathi
- Natural Sciences and Science Education, National Institute of Education, Nanyang Technological University, 1 Nanyang Walk, Singapore 637616, Singapore
| | | | | | | | | |
Collapse
|
50
|
Ehmke V, Heindl C, Rottmann M, Freymond C, Schweizer WB, Brun R, Stich A, Schirmeister T, Diederich F. Potent and selective inhibition of cysteine proteases from Plasmodium falciparum and Trypanosoma brucei. ChemMedChem 2010; 6:273-8. [PMID: 21275051 PMCID: PMC7162187 DOI: 10.1002/cmdc.201000449] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2010] [Indexed: 11/07/2022]
Affiliation(s)
- Veronika Ehmke
- Laboratory of Organic Chemistry, ETH Zürich, Wolfgang-Pauli-Strasse 10, 8093 Zürich, Switzerland
| | | | | | | | | | | | | | | | | |
Collapse
|